<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2205233682
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TIMOPTOL .DROPS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TIMOLOL MALEATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        %
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Ocular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Eye drops, solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Dropper Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        27.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="FAREVA MIRABEL" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            FAREVA MIRABEL
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MUNDIPHARMA PTY LTD
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        S01ED01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>TIMOPTOL is used to lower raised pressure in the eye and to treat glaucoma. Glaucoma is a condition in which the pressure of fluid in the eye may be high. However, some people with<br />glaucoma may have normal eye pressure. Also, some people with raised eye pressure may not have glaucoma.<br />Glaucoma is usually caused by a build-up of the fluid which flows through the eye. This build up occurs because the fluid drains out of your eye more slowly than it is being pumped in.<br />Since new fluid continues to enter the eye, joining the fluid already there, the pressure continues to rise. This raised pressure may damage the back of the eye resulting in gradual loss of sight.<br />Damage can progress so slowly that the person is not aware of this gradual loss of sight. Sometimes even normal eye pressure is associated with damage to the back of the eye.<br />There are usually no symptoms of glaucoma. The only way of knowing that you have glaucoma is to have your eye pressure, optic nerve and visual field checked by an eye specialist or<br />optometrist. If glaucoma is not treated it can lead to serious problems. You may have no symptoms but eventually glaucoma can lead to total blindness. In fact, untreated glaucoma is one of the most common causes of blindness.<br />Although TIMOPTOL helps control your glaucoma it does not cure it.</p><p><br />TIMOPTOL is used, either alone or in combination with other eye drops or medicines, to lower raised pressure within your eye(s).<br />TIMOPTOL lowers pressure in the eye by reducing the production of fluid.<br />TIMOPTOL belongs to a family of medicines called beta-blockers.<br />TIMOPTOL is not addictive.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><em>When you must not use it</em><br />Do not use TIMOPTOL if you have an allergy to TIMOPTOL or any of the ingredients listed at the end of this leaflet.<br />Do not use TIMOPTOL if:<br />&bull; you have now or you have had in the past certain serious breathing problems such as asthma, or a history of asthma, chronic obstructive lung disease (emphysema), or other<br />breathing problems<br />&bull; you have certain heart conditions, such as a slow heart rate, an irregular heart beat, or heart failure.<br />Do not use TIMOPTOL if you are breast-feeding or intend to breast-feed.<br />Your baby may absorb this medicine from breast milk and therefore there is a possibility of harm to the baby.<br />Do not put the eye drops into your eye(s) while you are wearing soft contact lenses.<br />The preservative in TIMOPTOL (benzalkonium chloride) may be deposited in soft contact lenses. You can put your soft contact lenses back into your eyes at least 15 minutes after you have<br />used TIMOPTOL.<br />Do not use TIMOPTOL if:<br />&bull; the seal around the cap is broken<br />&bull; the bottle shows signs of tampering<br />&bull; the expiry date on the pack has passed.<br />If you use this medicine after the expiry date has passed, it may not work.<br />If you are not sure whether you should start using TIMOPTOL, talk to your doctor.<br />Do not use TIMOPTOL in a child.<br />The safety and effectiveness of TIMOPTOL in children have not been established.<br />Before you start to use it<br />Tell your doctor if:<br />1. you are pregnant or intend to become pregnant<br />Your doctor will discuss the possible risks and benefits of using TIMOPTOL during pregnancy and a decision can be made if you should or should not use it.<br />2. you have now or have had in the past any medical conditions, especially the following:<br />&minus; heart problems(such as coronary heart disease, heart failure or low blood pressure)<br />&minus; heart rate disturbances (such as slow or irregular heart beats)<br />&minus; poor blood circulation problems (such as Raynaud&#39;s syndrome)<br />&minus; lung or breathing problems (such as asthma or chronic obstructive lung disease)<br />&minus; diabetes or other blood sugar problems<br />&minus; thyroid disease<br />3. you are already using another beta-blocker eye drop<br />It is not recommended to use two beta-blocker eye drops at the same time.<br />4. you have a history of allergic problems, including eczema, hives or hay fever<br />5. you have had an allergy to any other medicines or any other substances, such as foods, preservatives or dyes.<br />If you have not told your doctor about any of the above, tell them before you use TIMOPTOL.<br />Taking other medicines<br />Tell your doctor if you are taking any other medicines, including any that you buy without a prescription from your pharmacy, supermarket or health food shop. Some medicines<br />and TIMOPTOL may interfere with each other.<br />These include:<br />&bull; medicines for high blood pressure or heart conditions, including a group of medicines called beta-blockers<br />&bull; digoxin, a medicine used to treat heart failure<br />&bull; quinidine, a medicine used to treat irregular heart beats<br />&bull; medicines to treat depression<br />&bull; medicines to treat diabetes<br />These medicines may be affected by TIMOPTOL, or may affect how well it works. You may need different amounts of your medicines, or you may need to take different medicines.<br />Your doctor or pharmacist has more information on medicines to be careful with or avoid while using TIMOPTOL.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><em>How much to use</em><br />Your doctor will tell you how many drops you need to use each day.<br />Use TIMOPTOL only when prescribed by your doctor.<br />The usual dose for adults is one drop of TIMOPTOL twice a day, in either one or both eyes.<br />Follow all directions given to you by your doctor carefully.<br />They may differ from the information contained in this leaflet.<br />Use TIMOPTOL every day, at about the same time each day, unless your doctor tells you otherwise.<br />Using your eye drops at the same time each day will have the best effect on your eye pressure. It will also help you remember when to use the eye drops.<br />After using TIMOPTOL, wait at least 5 minutes before putting any other eye drops in your eye(s).<br />How to use it<br />Instructions on How to Use Your Eye Drop Bottle<br />This bottle has a unique &ldquo;finger press&rdquo; area. Please read the instructions before using the bottle. When replacing the cap, turn it clockwise until firm resistance is felt (approximately one full<br />turn). Do not over tighten.<br />BEFORE OPENING THE BOTTLE FOR THE FIRST TIME<br />Make sure the Safety Strip on the front of the bottle is not broken. If it is, do not use the bottle and return it to your pharmacist.<br />You will notice a small space between the cap and the bottle.<br />This is normal.<br /><strong>HOW TO USE THE BOTTLE</strong><br />Before you use the bottle for the first time read this leaflet carefully. If you have any questions, please ask your doctor or pharmacist.<br />If you are wearing contact lenses, remove them before putting the drops in your eye.<br />1. Wash your hands well with soap and water.<br />2. To open the bottle for the first time, tear off the Safety Strip to break the seal. Then hold the bottle upright, and turn the cap in the direction of the arrows until you can lift it off.</p><p>ِ<img src="data:image/png;base64,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" alt="" width="242" height="105" vspace="0" hspace="0" border="0" style="width:242px;height:105px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /><br />3. Locate the &ldquo;finger press&rdquo; area on the side of the bottle between the vertical lines.<br />4. Hold the bottle upside down in one hand, with your thumb or index finger over the &ldquo;finger press&rdquo; area and place the other finger on the other side of the bottle (as shown). Do not insert<br />fingers into base of bottle.</p><p><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAMUAAABZCAYAAACOnODIAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAADTtSURBVHhe7Z3585/Vdd8f7RsCtCGhBUlIQkiAwWzGxLGxU6+ZLO20STrNdPqPJGmSmbaZtD922kxnOu0kbpzGqetJE2PXBi8YY4yJDdgYswhtoAWQhDYkIanndd7P+/Ocz8PnKzA8atzO5/3V1d3OPXd5zrn33Pssn1kXA80UU0wxwuzWn2KKKVpMlWKKKXqYKsUUU/QwVYoppuhhqhRTTNHDVCmmmKKHwY5kf+f3/qANTTHF3x/+8Pd/tw29e0xXiimm6GHwleL1Y8eaWbOaBq6zZ0cgMCsSZs2anXH8OXPQxVkRn93mJVWGM5Rp4SIfRvjQXrhwIaiUP2fOnMhSnsPQQnOBcAvoSXvzzTeTx6JFi0b8Nm7c2Nx7z93Nm+fPN+fDUezCBfyL6RYvXtScO/dmM3/+vGbevPnNm+fONW+cOZO0lF+6dGn2RfRNc+rUqaA/FzwuRv6sUfr582+qXZG+ZMniZtXKFaM+QoM/E/p50BsubxDPMQq/nwfMy+mOXwrQ0ld8XOXd5wecNxP6ZY2fhYdR6/9X/+aPM/xzu1Jw8WmoO8aFunjxQggHgnE+BPR8pkkQL2a6wuQrXP0L+OGCoIEjQm+XaUGT9UTYPBku8RYPQDz5te7w4cPNyRDkuaFUKBYCPnv2nBxsBIF2ko5/7tzZZs7cuaEg8zOf8iiBgRIsXry4mRs0XCvGABCeM2du8gOnT7+RzhfU/kygzbhJmJTuesiDd3Uz8QGm6aOWc77j+H2elbY6o5atfqUjrZYBjvd9lx8SgyuFGilHkLh9YAFFOQgzs6IM5Fs5LLQIe87cWUI8rBxGriYB0hko4io37uALzp4925yN2R6cCf/QocPN3HnzRsKk1UwDzuoyL4Rc5dVGlAJFAbT97JmzWZY8lGrePJSiu6DZpohCA294nTx5ss1Vn97uAr+VX9dGUMv3eThtEu+afik6o9Y5E+hfxaV4Ot00fbp+Pytm4jkEBlcKo+uowlo9NGASfM3aXkFEIwFWWmfS8F/mhZ+DEQOF4M8OH2da0YeQhQAmn3AeVHzyzkfauRD28+FQpKd/8kzz+uuv5wyP4EJnBQGYVvNCaVgtUBLylyxZkrM/YKXBxDIWLlyYiiPzqbt4MhtZhWK1eONMuDcyHWSbI8NtNVwWf5J7O7wdjeus/Bw3+jzejqfHTtdxZj599PsPvZ3jfdT8ITG4UngFqEqg2Xe8Ew5bOeogtl47UBkQTQhoDjrlwpFvHxrKoyRtYaVnUHsQgKm0cMGCFHZWiBMnTjR79+4PpZiTeZrRZUbBD1NnTsTJZ2U4FysNK8KiRQuTHzTHjx/PMG2kLIpBefoN3A+ZaHNSeV9//Xj4ndK67z8LxLcTavMCDpvGrl+P46bv8zEmlQU1rYb79IxLrQMQr2k4xyv6dDVew0NhcKUo45AdsJKQjpOt3Q0K0IBUpdAAyUWZ2KiSD33uG4IfwEfASEvCcCMlafPNE3BhEMqrly1rrrjiitw4g5defjmFH9h86gS6yc21Zv/YZ0R9rBpsvheEcgHqYBUB9BUFWrRwwagdmiAyOBIO6sOMcvv6foX59AGt6aGZFK6YRP92vJ1fyxlOAw5fymdsKkir+TVe4XTXLXnq6CaVeS+4DEpB5+lAN/Ayj9SRMqajQVJnResOk+Q45UHGQyjbiPYOKEU4hK0tlOkArqk0EaeO2aEQmELEr7rqqmb1mjUp7K+99lpz8OChZl4IepaDtlUggHl0+vTpZn5bln0JaZxO2Yw6EybR3DYMFsZKsjAUA2T3AtG0COv0jXYdC7Pt+AkphseqD4+BxkjxvjPeSVrl4zCoNBVOr3mEdVjyVnqjz6sfB5UvbZlpDAzyoMlr3cLlhsTgSuFGciGlHJp1a+c1GAiufOV1F4m0OuA69iSkNJSAVYA6OqpA8pUQpbK0wmSFITyv3ShjCoENGzY0V155ZbN7z96sAyFnfwE8+LQfJaBONtKsCjogaGLFWZJ0Z9l0h+v6dzGPf1FC0uJfgNayIZdpBU/2M6xEwP3/1kPfbh566OHmzz77uebAgYOZ9tf/62+af/1H/7Z58smnmoe+/XDzaigycBmNYRevcB6+8yfRAbe9j5pOWTmFf/jEk81Xv/ZA8/m/+kKze/eeHs3k+modNdyn66O2A/TjQ2BwpeiEXIPmRsvpfoFnb5zKIMgSZtEpzQPUbcTh2w4AcVzwIsVmFD60IMuHy3g4BBSBt8+Mf+TIkTxKZS9iAfTKg/BaQWDFakFbKE89xEm/KpSKFeDYsRDw2EDXC4uZNn+ejnFrupXl7NlzzauvHokN++ns38svH2i+//gPciO+Zs3q5tpr1zQ//emzzUsvHWh+6zf/cbN23do027yPAbW/hKtzuv1ujOWI73rxxdxbmaYP0pzucjYvCaPYT/3o6TQJn3zqR5nmvOrg4TyjH6+oZSsuVWYIXAalYKAxcegMcaXXQbVC1NVAq4PNKdFbwTqfspQRj0hIekAeNXSzu2x3BDv9ogyk4dgQ43O/4XgIxQu7dqUZxQY8FaKlo4z5vhFmEnVTFj/jUffixQuzDSdOnEpTygKA8FyxdEmzJBTPY4CPY9UhH0XinsmJ2GO88sorzeJYYc6c0R6HY+Nnn3uuWbb86rxZuGL58ubW993SbNq4Mbuf/W75ART9e499P1cU4Hx8eFVaQJhV6ZHvPpplgX1AOV8XwEqA4oKfPvtcKtOPn/5J86F770kz9N4P3jPGHzgOrz4ulQf6vAzTz5T/XjDnXwba8HvCg1//RvonT57IhrqxCneNdx6dYnZVugSeuCAalzFqfBSGro3j4MNFZMg4NbIwLwizif0DzkKOQ+hdDuHEzp8b6UuXXtHeA5FQAV8ITCd4oDSsfNTH7H327JmgUf78+QuSN2WyrjABtUpawGiv263VkMlk3bp1ze3vv7W5/vrNzdatW0Pgnm6+/fAjIXBH8uTriRD2Bx78ZnPPB+6K9IebRx97rHn88b9rVq1cmavS/V/+Sgj495rrrtsQq9/s5t//hz9prt+8OQT55eY//5c/TWVD+a65ZlXW/UysQt999LFYiV5uli9f1hw8dKj5r3/62Vj1juUYYqb92X/7XHPzTTvzQOLPP/eXzd1339k8FSvCg1//ZrT1tmbzpo1pgn7kw7+Y43YpqL/tteuhpnuswUz0BrSYlOBjH/1I+u8FlsLB0HWGjnSzO855dFLCqk04ef2Oq5xXlG6l6NAKP/ltXnWAOnwqxCabeH/g4eF04qwaz8QMuOvF3UnD0SrKhYD7mBZ6mU7qB3XQDoQS9lSPScFmFLgO3fHW5l2gvFYjrRhnwpw7ygCl8oJbbr45V4fPfPqT4T7dXH3V1RFfFibXa2lmPffcC82+/S+lADNrP/f8rtzLrFq1svnaA19PHq+8+mozf4H4fe+xx3PFAJhg/+MLX2xWrFiecSaFbHwAM+h49OFL938l+3o4VrDHouydd9zeLI1+Pvyd7zaf/tQncvW69tprm7Vr147aDBgbj3W9Jvadbxqj5l8KlffQGFwpPPOC/kpA++W748p3/7v9SMbG4h2NlWV8MFAMAwFEkK0sxDGd8FVfN6A44uQ5H6F5YdeLzZ49+5TWpiPQ9M9gxu32BmdjtZifJ1KwZ89R7X7arPsbi4Jn25kWql/jhmCiGFpR1Cdm65WxEhjbt9+QgoxyGCsjvivavHXL5hRiVol9+/dnfdtv2BYrpU7C2Je875abM4wSI+QoGOBEzsfM/+Kf/3auWvBaH/uYzZs2Zfpj33+8ORAmJiYeCuXrA2h/dUaN1/Q+zMu+aWsdBuMJLsXv3eKyrRRuLAJgYQNaFTqzBnqK1M6RppVFncfpCNCCMr6K+O40ggjg5XsYAMGtcBspW9tbFRohfzE2oKwc2P4oGXneeAPKokAIHvWxaWY1UH2zcgU5FRto9xWgODLfEBRSNB4ojOlOnjzVPgoiZQOYf9AfOHCg+cEPnoh6z+YK8aF7P5j5nABhCrFSAPf5jttvSx4oyNat1zcbr9s4mtHpj1eN9aEAKM+evfuau+68PTf4VqpNYR4ZxFeH6QW2bd2S/lsQfD2uoIZBP+4xJ915Dtd4HzV/SAyuFFxgGprPLIVv84gwfWf2R1hxhA3lV0WRwDJg44OWwR6NBhZHtlcNFIU0C7v5ANXfKRcgH8EcCSem1DPPhllyMjff7CFYLTrFkNDiYI0P3zzNCqGHPycyKEu2Ldt8MWdjj4lBvlYiPaLyeqwyp984naYPWB4mFOSvxt7ixhu35+qxdcv1MbtfmfnM6mtWr86ZHXPL5hImFti9Z0+uCrTT1VI/ewmU5Tf+yT/K+NFjR5vbbrs1w+wT4Pfii3uaJ0LpUMLf/me/1fzvr34tleNXf+WXR3yqH4HWa+OBGu5fC+c5jXg/DfQnsZo3JIbfaJ84nkLlBttE8r0Gd0Z9UwfVUeitBLW8fZlFyle4xk2XkXbgAALMSRE+s6fs944/QkzcIJ324DPTcyrFQ39XXrm0WRiCcDGEGR7Q6JSN+w1hOsXsq2egeGgw6gmePGOF4rLxtlkCEH54c5FH7Q4+hG1a+T7K0TClOJF6f2xowU07d8QMvTXr237DDc2aNWuaLaEcKMR1113X/OQnz+Qs/75bbml27rgxFQEz6boNG2Izrs01wCP8lRDwf/qbv5FCThp0V115VYYx0bZcf32uHOxX7rnn7mb5suV5GPFLH7svVxx4eLwqSNN17QBNpZ9Upqbbn8THcN5D3/5O+j+XG20arM7B2p1DyzVIymfvIaH2SmJAo0dDuvsNwIqi2aIbdBw8EL6c8ds0lQ+hizq8yRafbqAtlHXVAFYate98s/+ll5pnn3s+HwuBF5AJBJ3ahvlEGMVgZeCOtgStvXt97PXk6frJq/sT2hr/J734zs5Z/JsPPZTmi8uysaWtKLiFcm0oAcehf/O3X8oVhJMi0lld8hQtqpSvuo39wR+YBqBAFSgY9Wzbti1XIOjuvOOOkQlGW+zbMY42fw3XTT5hl5sJk2iI9vtwOTC4UgB1SBeZjiEUmlWVh0JEKPNsW9d8d7wOigZaQqx05XU0lKkXhvRuDzATX8JqX7c0A9MCZm0E9OlnftqaSuJlux1SZn5WJHgQTsVYuCBoeJRcJ1TsL8yXdAsW6NqmPjJGTzz5ZJiAF3KVcP9xBnXJ6YTpqR/9uLnz9vfny1MV5OOAJ6Djx080DzzwYIa5rwEqnTEpDfTTPOmNj2EbCNR0h01v108DdcIENR/ncRsSg7959+orh9MXV3dOQtQ5dY6wT12gzRLhEUcoECYgeqUTpozMjHGejsOLwWQmZuZbEMKKAKIgdX9BG6wMnvktdA5bYRBqyqy+5prm5pt35rEk5TCRUBTqwyxCEVAIymPicNOQTTNptAvF4YTKYMOMsmgSUdsN0hkHytCPReGrfxqLPjBxPNO7f5cKazN/McuYH1mV9p2Daz1eBj6OV1aVxso0qS6S2qaMwiZz2Pl/9Mf/Lv2f83e01VGeJUIQZS5h/viUyIPQKQ7OKwdp3axoWtA9V2VA68FRvaqrDjR12gGVcd1aiRB8HGFWB/LggYDb1Hn5wIHmO4882uzdtz839CiCzBitKNxrQIgx6fzqKuYJygI/v7JKtTgU5IolbMxtinVtZh8CTd5xj433mVC+SXAfqumze/fuPD5FYTGtCP/02WdHce5DQL9kyRW5kWa1oO3mVdvhtD6cLl/0lXacR3XjY2+YXOMgWscresUGx+BKQUcRKgYE4WQGxCEcCBz5pNNRzfhdE5TXn8UpqxtwpJkGH57m77z4l/EYyjE+BmnEa5qUds4o3YqBM1/K0VYcd3vZYxw+/EruIXg7z3mURegXLpif5TnyREF4NxvlgYYTKa10Ulaezu1s9PQS0Ghlm50Ci3K8mY/Ru69yoPoo7uf+++ebBx78eq4eHIJ855HvNv/zi3+deZ/9879ovnT/l5tXw+Ti2a+/+MvP540+P2Ro9PnXOGBM4l/6FZWmX17hzlU43uUrwXGHK3pVD4LBlUKCKkF8881zKSSkEQfjs/i4YAMPBGB18WCOu45ey6/K4YC8NoyLBOqnLrcFh8D5ZMplndd3lT/03LHeu3dfPgfEisAewfkcYwLuSVAfikEeR7X0Ozfj+RqrrihpbLy9RwESOJmRrK5fuv/+5ujRY6lQF7L/XXv6YMMNP9yyZcvytIo2feyj9zVHXjuSYTbhK1asaP7qC19s1q1bm+WuXbMmfWDe/Tr69TL+Hh+g69rROR2fvDqWzgMzpddwH2RdIvtdY3ClYCZ0x3xhKxx1uga1GwgGp97bwMHT6AY9vYTLktfVG+2ItFSCnjIA6DAlXIfL2pkWV2kAPvzY3HL3GWHV6odTn7nb7ZXQioGAYxLBhnwQbJM3CoKCQuN0QPmvf+NbefRKWOZXrBZW+pbQbeTmHs9JAd4OPHDwYJh6+5o7YgPO8Sx7IJ5x+vgvfSxXCkyp/ftfSiVhFenDfXY9vhYeR+cbk9JJc7xP73aD/nhX1DSHa9qQGFwptt+4I2fSCgYSpwHRoLjzMhGkSDavtAroqBU6fOIeUI+DVozxgYLGDkLuducnbPDDrEFA6+pVfRzlzMu8XW8F/eGRDBSDjx/AXy8VqY+URYDZbKPgCPK52Gyzh6AsdXECpJVAdbHa8PiEBQ88+uj3kuMH7r4r01kpMN/8XFW/ba+8opt9AFqezn3+hV1ZPvsTDqV57PHHR3sUVhSUw4cHfQdcT033NTQI1/YQ7pczHD/PHjMcZiE+q2C64G24HLwqn8p7SAx+827nzp05K772mi5O7Ygarw4oLhMJM8Yda70EfUYQTKuyOAu++HtwTA8/IpgdYwMHbcYE0sjnAngf4XY4TL59gO/wqG0R5v7B0iuW5OYbs5FVgr0QtHljL4QYWp1yYULJtIykNLPwgU058nhMm2PWz3zmU2MmHjcLCbMSuC1qRZNPv/LE7N133Zn3Nzgtoy6euoWWp3VPxj7jvo98OGivaVaGCQXttm1bMw5cj3lXOO1SeS5v1HTnZZi/Ng03xjOCXC3S3pIX8Ngb33745/jmHTPgps2bm1WrrskL65nYIGwH6JhOY/SJGO83OrNKg1rHBFoPCL7L5EjyP+FIZ4UhP9uBkIfDd/3QkSfh7C6OeYjnOEiDxnlcHMCsD5jtEWArpO9rcEpFexDoeXN5iFArJ/Y9sz59AKRhYp04cbz5xje/1Xzqk58YbcI1Prg5WY7NN/TZnrbvYOu2LWkObbzuuszjHQdAGCX5h7/+a5lP/IYbto1oTQPgizOcbv+doJavYCXoY6a6an01XtOHxmVRCi7qrbfd1mzZui0uaPcCP3CYi0sYegll1+mOnrgGkLQ6EA6TjvL04fyqhP60TdbZztSEuzaofmjt44DzKugDqxICf+r0qdgnnMrHO3TKpPshlPHTtAg+9ytI8yxPmE27JwDqY4X52y99ubn33nvyyVVBQuqJAwWjnE2gKD3RnwnuD84gTB2GxwG4rY47XOPVBy5f0yKWvg8LZkI/b1L8UuXfCwZXChqKkCEEmFIoh2c6BtaD7k7htBTKhKGfFlB/FMB03QXTYHjPIXQ0dt5z4LPZ9oYb/uwzmMU7M6YbYNdXnUF9tQ4cAns+ZnuENKjzwUGef3JZ+HM06uefeJebI9q5uWJoYiAfYacqFGLHju3NTTF+QPXTN00kVkS9f3Ek+SVd/BlZd/mbBLVdcFtVl+ucDOd5xq9lzLOWJ42421HzKpzeb5dBes2r4SExuFIAOpKCF45jv9tvvyOW6BWjPHcGYVVYjtm1m51QLgmrzaNJg0C+FEP3EQhbUVAaBI5Z2O0h7k03cSsFcdftunDEs0y4fh71aQWYnRtFnqp9+eWDzaHDr+SzTrqLjdkzN8sj+CgL9SHQS5cuyU0u5dmHHX/9ePPII4/kBv6eD9ydqwl5eZKWstEpBumMC2YUm2uvQH1kWv5761/O1u1f0pa/itz4trQGYdpRQV0ee+D25Li2ZSe10ejzc53pt7x9japjgz4kBleK2nCHrwwT4K6772puvuV9KUSAfIGBIKwO6oLrhpVhwYYXUJ7KW2GIq2w7sBHW6qMTJ7uRYgQvFIJXPPGdTx0O44AH3w5QFysgsz8mE8mnT53O+OrVsYFduTx4nU8lOXr0aJaBN+9KcLMPwWel0h1tfRGEd55/8MMnm09/6pPBe0Gm8bUQTKbsYjtW1M1qIYXUx9VQOLfNGMXbITH6dCB6Jr/NI+4/EKOcfh8ILIBuFA4eIz6E+Stp7wSmdxl46DoLxJ0/U9veLS7LSkHjLcBAgnYhX1lcv0GbPy64Oww0I3oGxidVcVyaQC0f3+FWPRosFIVyCAm8hPH9RhX4bB+DSnpJw3e74Ft98vMiRLwTyqirzceMgYajWNq5fv26ZtOm63JPwQcR1F7VkfQxu3MTj3cfeM7pu49+r/nofTo9gSV1jR/T0i7VZZ924PK9jeBVoXEx/VsB/xyHFkE9Rk/c0EjJd9j0o3gpW+nBpHZQv8ezn99Py7ayYphfr+4hMbhSeKAt9BYkHLM0ioEwERcNFwWhZyB0kTt4QLtmiqf4qazScoA8PhHO78wGfyuY8tUeVo/cY7QCyjFqhqN9Tne7+/CFsjAmTUunOi7kCkJfjx07ns8XXb95U26IuT9AmTOhDBzDUgeKdCoE+msPPJA313i3GlMK8yo4Bs3FZsHCBXljj7jHBJ/6vDLC63isFjaj3F874LDzVF5jm3ktb9N55p8JWaKlnVSmn19R4/38Gp8U9p/rert2/qwYXCkMC1W/U1zcG7bfmGYGcS6M8wAmh9OZ9SUICJxsa4RA5oTSAfQuj4+gky8Fk2A5HxCEJleFaGcmBD0mVSoJ6YWfw1ZYfAQfn3qCImi0PzJvKZbe08YE4i05jm15MpU83otmcqBtX77/y2Fyrc5HxBFS+GIO0Q5A/dwYRJHUbzloiWuF1PNRbPa9l6kY73/Xtwri/TynzRRXezofRG4b6mB6UMOgHzecPlP+5cJlWSlwdbBqGgLBszZbt90QcVdPp6FpY6MxqPcuMLGkKOYJKn+5btbQnXWtAqoD3qIjzcKbadCQ3ubZmd6wQth0Ik93l9VfzB02z+qryrGPWLbs6mbDhnX5OumePXuaH/7wiSz/ox//OD989gv3fjDLchMQXpQ/FZto+g0faOHrEzmvENDRJk6jCLPKYIqhGMRNY9Qw6PfvUmA8DPNxWfyaNhPf2qYa/lnQ5/uzln87XBalsI+rguU8Hnng7immVDfQCDe0inXlu3IeSK8aKtPlgwyaPoWWkPM7Wpej/nwMBAUhLeL4FGSoqQ+BdBnCVSFytYE+gMkGPWaYVkKZkWyo2WfwcB5fPGdD/eLu3c2uXbtSOT70oV/IcowLwo1yAEwwg3aiCAsW6KBC40LIAqEVg70M33ZCOfwoiNsHCNd4BW0A5DtsTEoDtUzlXcOg0tmvNJV2Utql8E7p3ikGVwpAIy3skxrsvC1btzYbN26KAbM5ZCHXLA0wQTpzBKWRktULRNj1kOw8ZlAEDAFCQBAYw2XSBV8/H5X1tPW55ZqJ9Y63Vonuh1loGy562swJgSY/OKaCUI5Zm7J6kehivlvBQ3u8XPTVrz3Y3Hffh5trVq3K+jiRQjH0+xc6VWKVYbWkeziUbckSvU8N8ElH+XDQwkN3vN9Ivm8Hj4PGV2OLD5xmuN+XgvkZNfxO0S8zE89++hC4LEoB+oPH4NYBJgwNinHD9u15MaOL6cZpuNjd3kI8uotnh0C4TpcnbeHCRSmUElwwPohuUz4CEjTMzqOVI9LsEFL2QwilTTjSgeqdld+MhRcCDw8exlt2NR8BUPvYTzwbq4RBHfff/5XmP/7Jf2qef/6F4KdHXqBHMfBZYWQKtYUCtAPlY2XItsd4ANqIoxxt6J9Iud/k1zEwSMdV0O4++jQuV3maxmnVr+Vdzr7pjFqu+sDhym8IXDalABaafkcBaR6I9evX5+abH1us6dFdKCPOBfem8h00Oeigxfl36hAW2gNfXG1brZN0VopUooijJKSjWNSNMx2+wcrAKkCbyWPTy2kQp048EMhGmbS/+8EPVaAFSvbxf/Cx/EoHQs6Kxuc3WY1YmWgXm3VWuQjSpEzzTT/qIw7cD9Lx4cN+BQVxW/FN57j9GraPMy1wXh9Oh9b0tRzo8wL9uFH5zFQnuFTeu8XgSmFhsdD1UTuRAhgOm3tVmBB33Hlns/n6Le0syYUVPQJqR9wDhrMAuE7Y27ZnSMmHH88QLYqZm9nYJ1yeYd0O8zQvFIIbbXrPQSdPaoMVomsL9xrYJCPM0HLnWseoF/M3KDCfeEW04uqrr85PT65evSYVSDM9XwnULF8fM+cGoFYR2qCvDVIfexAUQ21hLPSrS06HDydZJ6MN9Am4fzVunzTHjUo3kzNm4muYnjFzfNxPbxSfBPJqOy9F+25wWVeK2ljCM3WCC08nmRk3b97cvP/2O5o1116bA+fB42KDvAsdzjfwAOWDa4ahzw1zW0eWjjR48+YbMyypGlQyBRQAvvWC8gE0PnoAEEzTMJsTlnDKXOEGmzbJ/LywjlpZGXi+iXewKc970cYvxub6k5/4eO4ZyAP85BcrEnyoh/bpbrfq4NER6mRFgT90V4d5hgIC0nHQSsE0sTDpvBGrBXUZ0OBG49TG3wko43I1bPR5OQwd4X6Zcdo2UFD5TapvaAyuFO50DePGO9510HAYYUMwbrzxxuaaa1aPldUsqJnY9jf0EmQEQasGgJuVI49bA+Qh5CgGggsoa0UACCgOs8smE7SqU7OThZgwpzzEWRVcN4998I42G2Ly+FYUHzTDDMJc+vVf+9Vm69YteaOOL/y9dkRvytF+vkbI6gQvhJkfmdHLS6oPHvQdoJx8M7Z+0ylI2rAVQzcYGSv2Jmy+DdKhxREGHZ927Nr0GtZq+9a8GvdYOS7XrTr9etwOp1eYT0W//JAYXClqI99pmIFC+AjTWeK4rdu2NevWbwjhlAAjNNDhmCW54MEhFcMzN8jhavniXAd+CnkImj97Q1wDrDbBE7OEO9EoBRDv8xmHFjrgU6grgx5hB87TB9j0yAmCyLdeN2xYHwrxK83atdcmTxSK9xv42TBWAWhpJ/cn2IdQJw8qYkZ5X4Rw+1kqwOPwlCOfsoAm0CXahpNiyBxktcA3aK/bDAhrPMSnD+WLf7/sJNR8lVHY18NweFIaIDwp7j4OicGVwp3tN9hxfMCFtEA6DVDe5biY/EbDjp070/QBNqMscPgSVptW+rYrYYQKfilcrWBTF492MxuzAiBMKJjscf381+IwWSyE0JsHfN0/8Tyfq87KlStGK4/rcJ8wZzh14uMBv/yZT2tFiXTo4Qd4gNAvDXFzDmXh8Q/ayUadWZl9Ef2lTRJu3gHX2NEm7V8E0oHHUU4fQICWjTegieQZbjO+xrbLM12lBxRpi2U7a7zCeX1Mqv/t4DKqqxvroTC4UgAGFFiA3OjaePKc77guRPf4N3n4vBm286abYoZdF8Kqt9bIY3A8plKO7ug2amv4VVWUxIIa/+nmXDgKMpsjZAgiQopjk+69B/zdDjsEGX7G8mVXp1J65YImb/61ILho0eLm1lvfl23NsYkASkuYDTYCTR/17rXMR1YX/x44CkOdHPEC6knFCXMIwUXgqB9Fzn63AojPeFCPTEt9goeyyhu/JoAojlUX57jp+vQVfYWpcB6eeYLKz+klaSytc/HfZcTgSkHnabQH4e0GM4WkgHJ2gHIIBEJ6/ZYteXTLc0L6srcuNLQO44sn5TVDJoIGXlVgAYqRq0Pwu3bt2nwpik/M5weJV61KRaltd12YS2tihkdQMaNcLw7B06zM6nIu8/MdjlhZ3C98+OJzL4Lfl0AZeHaJNBwKiA8/wmz8GQe3h2epEO4gSfCMFTwAaSiM8sYVg5t7lCUPVtVV1H5PosPPCWYG9OnfDrRHbZJSO81+l9+lXQ4MrhQeyDrDGk6rcJyLD/plajrKwcaUG3433Xxz/uSvbqZJwDpe6Y2ENMORmLnQRBi+pLEphgcKceP27TnzMxOzueV3GNgHkE8an6bnaHfD+vX5QyacDAEEkVlVJptMLd88QxCZwTGDtMJIyC3cFnpWBcwoZnH4AHweCxGN9hesKvAjDaXjuJUwvGgjfKnTaLubNKymUgzdw+DGnvJE2/c9dhUeYwNewPUAfKfXNKOGK8y6mm3m26s249UNicGVAowLqC4Y4OJPQh18aD2goH8RZBroc/d8rYL9BqvHipUrR8IbtYq4Bfw8o+VXyCNOnUtiM41icQyM8HMxEL6RQgc9v3zqL2/zOAaKwnEwAs6qAz/uQUgQu3rhQR3sXTB/iON4DZWyrEAokx/cQxlYrXAok8eED63pax/jn+Ekn3LQcpQLPC4yozyWGWyhsfV9Fkw36o1gwmPrODAP81H5joY46JfrzLP0xvxK53g/H7ZOM+BpvobbNyQGVwoaaVi4PHBV+A3n2QeEqwOVL2m6gHrkgZtgfCqefceNO3akmbUuZvNrwsxCWa6KfBx0/D4bXxvZHqvCjh03hkJsyk/Mw59Hx0HW1dZLHzhd4jSKbzy5Dwg6yoXJwukQwhUls1juTWJWZhI42v6MMOBeBuXYw1AHqwCmFcjVIgqzEnIXWn3XyRVA4bUC6TOcnJCRT3mUkvK0lXK0hzZ0Y5deQOPJxAEt4Ai4Tlbk17EGHusK07RVlLq8p5ksrKS7bOuNwfnkTaJzPYba20YGwmVRCitDH1Up6EwdSMNp6qzSTds503kAVSeCg/Dy+3A8OsKvgvKDJigMplEqwaZNeQx61ZVL81klzvmZ4INrbMInXRApNSsEs/DR2AzztCtmFCdE2uxigumuN/QILqYNKwGKgElDmJme/GreUAb+pCP0uSdo62blgjf2v00pBNgrj1cMNtkctVLMikFePZEiL4csQBkpLfdkLuS9D/iTX/vtsNvXTwN15p6UZ1no5zkOFO5oAGHX67j9SW5IXBalMKwEpNFBjhH56VqAMJBPnumg8aABwuTVNA2CabVncL7qDtfW53Q8Lg5f3OAtLaVLuRA89hXwyfZQHsADqpYHefxaEFWgGJwW8flJ9h6sQNj2UgbucuvGH8iv37WzOGYN9x/y8ZJg1B8r6kIxGBvKW2HIgzf3JLxi5OlU5KGc0CLUCDegLoCphkK6n9CrP6wWUibaAD9OvtgHmaa2DThe/UozU7jymlQGJ5rx/H74/yYGVwqggdfFoUPEuaj79+1tDh861Ly4a5fMj7jYXHgAjcvZ7w9KpTFqHshohHmoL29soTjheKybr+NBgKBC3xbNMEIzl1MkVg6j5el6uW/AKRE2PJ+Z5N4BKwV9wezxngaTRv68TENxZM5E9fHnOvI7VO3qYKXAnCEMDys9fWRmRxEIw5O2M6bEMaWojxMq7nXAx/CNP+CxqkA5uE7Uw6TFZh46eODjyHccuj4q31o3MK9+Oqj8Kw/g+ipMX53Th8TgSlEbCxzm2JELxuc0+VbRSy+9lHmeDT0IdfAcxrdwOF7z7NLccHrQc8ErT8LmgQ+9AT2bYja1nlWDaEwI2HNgkvA4OJ/hRwj5DA2CzGqDKWIlB1296Y3AauWviSCwCAWKgZAjmMzugOLUL54aK/LxaSP1UYZ6pFi8v6GPJtA/C7OOr7Uq9IVabdQJGPl8poc0j5MBL9BPJz6Tq6jl7Tw+9mdCpau0hCfV9V4xuFKAqvk0nDg/VM4HA3Y9/3yuGEdDMTClPDj9DoP+BZSwjg8SNKkMFvCWT6UxxA/F6fg6H2Vi1uaRi7TFI+76Ky/ay6oADb8Zh4CyEiDkmCOy09ubhS0I42x/E2bWR1AtLFTBZEEd/OgkxQnjoHMYsMdgJfGjG3ymh5UoOCdvzChoVaeeqPU3pFxfcA8arU4eO5TJe5Y+XDc87Xe8OjgfOGw64uYDKq8+SKv58MBV2knlhsDgSuEO4LvRzKjMcDjuMO8O82n//n3NoYMHUxAQLAZLF2h8j6C0biCB+ZpOFzdc/AHnI/zJoy2vvUMIS/yNIfi4Ll4Oyg17+1gFQAEcpm/QsZ84Eysfn7FHIJn14cGDgPjM4PTbY4GPsnDjDJOLPiPUpPGzXaw2PP8EX1YKHxsDuil6f4BZj2pQDiHmHghtII+2US8/DwC9T4JYAevGG8A3/s96VBft1NO93GwElO377lM3/vINx13GqPEqI326CufDkzb267ocGFwpmKVofO0oMw9CwoNsJGPbHwjz6dSpk80rhw+nQNUOewAMyiiL/6Q8HqhMj3DWJ6JMH5lR4Y9ogyeb4Ko8CBLKkmXadtMe9gvkAfIwQZJPxD3jY0Zx6nPgwMGkpY+cMHFKhC1PW+HF6kFZFAAhBvjw5Y44R7D8zgWnWmzaoeUPdOOgvpJHGnVBgzIgYDjaDEhDMbhB5zKAFS37H2k4oLD6j+L5TjzfxXU5eBuk5ViaQcB0hgUemNblDIedjl+d8/rxd6pM7wWDKwVCzgVxp/FPh5168uSJNJny5CVA2u4XX4xN67F8gR+BqYpAOcfFqhtQUGkBKwBmgsp1dbNKzAnzIwU//jBxMD2gcRst/L74+AgUZgyCQn/gzWmOAc38EP5Vq1akgDLLMxPDE7v8zBlWAzbMPHbeCZ3ara8LclH5SS2+B8XqwGf0s02RTlvJdzmSKSth0MrB6oK5R1jm2OxUXsbS+SgkPGgvPsqadQTgY5BGeUw1ynOd/NVB8nCEPe5qx7jA2pk/6NNYqA3zNUwPnesCtZx9yvb5DYFxyRoAx4+/3rz26qujjjHAXDBMp9OxMnjAWC0Oxp6Cl/hPxOqCb6Gp5pLoFSesfAkZWQiPkadMkYcSwD9dy892Oc86ccMNE4k4MzY0CGnHd1aaRiiLvw7ODTJel+X5I18E7mxDw7NYKA4/3oKC5IlTmCsoIDz7oBzmDasDphTKxw+5U8/owscf7SZOejc24/yY0VEMxppxpm6dTqkcK/eIZ/iYUVJIxpO0zElaRtNj770RDsDfvsOG+cNDfATCfVoAfW1TdQZl+3FQ0ybxHgKDKwWDyIWwsFkpOBXh5hgDnzfJwtHRvbt352pxJGZMP8cDTTsGAQ2CBwW8ZQBTUDoBQk/w+csVohWkXB2gjLy029t02ooggRHfoMH04Xkn07EfQklAJzx6+I/Hx0lhxeCDx0fCVDx5UmYj9j9jgBnJA3/6IPLZVE6UgV8QQujz42dRf/fFOwkZF999k3KrnZShjZhfHBezX6E99A1lhZ7xR6EBXaNc19f0AuoLUB3akLPxhr8xGt8JIG/0FZQI2/VR0whXfjVceVRn1PDQGFwpGOCjR480e/fszgHSKnGiOcFn6rNjsYwjUPwL/403TjdPPfFEs3fvnrx/wU0kLgoXH9/2LrBwIpAIe+rLKE8CpDIKp2vLpAnThhEeBIoPlPn4E4HnLjDC5AuLMCFUCC72OALHzI4wqy3UzcaW11gv5stDfD+WjyvzuDh1+pgWMwqFYs/Ax+B4oJAbgKmcke++0SWutzfI7gdwGH68eEU7MQVpl8rpMXPifkmK8WNC0vNRWr1ZwbwCwlrs+U/1qb16FIXrx8Y7hTBc+lC2YbuKEU3UFRGFTWenxI7GYZLDZ6JxfEQPWroxXjV/AOhKDAwazHErZhQXKE2nuFi6eRb/4oJ7WUb4ofnxk082e0KR2GdgSnFBERQ72eWt8OcF7ISENEynjKfCtHuIlpYwPFRKwITh4iOYbFAZVwSY0x8E2BfRD9tBh/mEUDHz+6Uf6gQoN499kAYdCsb70ytWsHm+Mk0kBJVyeZoVdeeFDbgfvAJLm9LRZtLCp+8aAz3lSpg+ezXAZ+VBcdU+PoR2Ltvg97fJZxUD1Mv+aPHi/mmU2gG4LigPysnH1VAO2uz8HLC2/SP08yLuPiZ6YU9SWc6uRV65ErfywC/b6fSI/9x/SzYFNDqL0O/bty8VggHliE/mU9DE4F67dl2zeAk/PKgNIArzwnPPpXmBKcVRrWZ/dRxooKLJDErUgbOSoADwICziCLUOwKHGUQBmeMDMj52NqYBAIbyjctE+7gugRAg29QGEjE2r208Ts5/Rb9prh1Bp1s9rmhj1J8qpj+KJXx3jCCA3DSBd8W6s4YmyonBWXP3wpG7cQUf/OC0jDD203f5DvNW0ri7q0VidTUVLqEFyhIsbzeJmGMg4eXZtWpqLIhg5rw7Um7QlXn0UQbzgNiwGVwr6RsOZ1Y4cea05dPBAXgz/sAYd4fcqduy8qdl2g74nSxoXjhOpHz31ZD5C8dL+/XkxQjySF74+RNAqUStM/Fl4AIPEuHnTnWH8yPOAAupE0BFk2mxzQ49JSFEQLsBKhmKQ7xXC9rvvSFOGfia/iJNG+/Ht8iK2znEUBtS2Zb/oU5vmrFo2aSKd8aM9OAnum7nSQcP9C+ilzFppWLE9GcBD+w+vjJncQhFWpjRlIhOFYsyyYoizzFihtl3sG4swtzQZDnANo2Qbjv5YwAuvfrjvuO4A3+GhMLhSyMzRBeDC8FvN3HEFdAbwSDenOCtWrmqu27RpdKMI84G9xzM/eTpXGL6AwTNLOdDthc+VIgArzIsc6PiHEthFotIDlCGuskrPnBxcHQxgHqBkmBTQoRjMovQBUAZBok3MvAgdQDFQCr3vQF16TZTPyVgxgNvSh9tjeHxAtjd88uFrMvcjBSMTdUxKUdqLUuLTRhQERSFfr7JqHNhjmAcmUrdHoj67rm3wY5xwTA70zW01n74DOQYh8BmOtJGZE9m5erZ/7RVJEK9wvPr+y7rbvyExuFIADygzaz6YFzPoKD0Gn1k5EQO1fv2GZnl+S1UrCYrxWijDvn17c8VgtuVkxTyldN0gOt3jmvuITFMcEOSijMq1vqMILxccAWcDSlsQJoVjyNuZDIGjL9qQS2HyznLMtvCyQLBptwDAmzSAX+M1PAnkpQu66NGo/dWXMOMjnFIaDgg4piXM0Sp9YRLiegCUxQoLfzbVTAIRSx52rgc+KKbbyzHwaCx7CA6jPMLpRxmHASHSsk/xlxZAyc+Vo/0D1Yc+w5EED4eHxOBKoQH0xVLDETiHSefdA3qC8PGpmR07doZJpTu5gD3H888+m3uL/WFGMUisCigHJIy5VwmXyeGN9BSUdjXJi9PSAQtCoqQh+Ag37UTAUQ7eaGPDLGFTHSgoqwX8/GQqCoOyIHCEER6EjuNY91t1hIs4vNwewrVN2fYydm6jhaKCuqE3r+ozrvx6Ev2gNKscqzV7ILU5BPvEyVH9+GzS8wAgJ5VkFenipzYrjbGif9y5B+T5D3AdLNSOO1xBH0nPtxfNm3D89ZE8gkU6/sKnzCS+Q2BwpWAQEQwcgkLnmaU4EQKkcQFGiB6ycvDzwr6wOWCRvuuF5/PREH4ai8e6yc99QjtwxLuVoU2LPy5shi1cAXjiTAdsiklotaJRL/sGViQu/uLFOpniEgAEzF/yQ8jgyWysmVSKDlgtMKUAdWbdtCeYScjaNLc7PBx1ka80+teahAFPBC4DaLv6q1UUIPh+xkr7i1gt6FvQYv4BFNntQ9lpC+ajTcMK1wkN9VE95RF+0ilPmxFqXEUV3OxbG3cX6BNwMb/9aJCeK0k4SJNHxrv8odFJzUDQxk+DiODkl/biIuGDPJaNC6hOqnoGml9R5eMB3l9wAQ4dOticPHEiFQNbNu9Q4xAU+MQg5QUjwGCPBlgrkmKiMVSvBWt8RGkHikBZVgzCmFD0Q2aU6HkEBBNFm1QpKyAsEuK6+Ycj32Ujkh5xHHWO8gI1PGpnWwY43+W7FSOTM0y67l+obhSWVYv3N6CnnYAxRXmgt2LIjAJuh9pgB43GQuVRWilj1wZAPq6inw9QAvg5T+2XopIO3GdgOvW/Cw+JWcFwEI6/83t/0IammOLvD3/4+7/bht49Bl8pppji/3UMtlJMMcX/L5iuFFNM0cNUKaaYooepUkwxRQ9TpZhiih6mSjHFFD1MlWKKKXqYKsUUU/QwVYoppuhhqhRTTNHDVCmmmGIMTfN/AIL3jq0UsCK6AAAAAElFTkSuQmCC" alt="" width="197" height="89" vspace="0" hspace="0" border="0" style="width:197px;height:89px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /><br />5. Using your other hand, gently pull down your lower eyelid to form a pouch.<br />6. Tilt your head back and look up.</p><p><img src="data:image/png;base64,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" alt="" width="250" height="126" vspace="0" hspace="0" border="0" style="width:250px;height:126px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /><br />7. Hold the bottle vertically and put the tip close to your lower eyelid as seen in the diagram. Do not let it touch your eye.<br />8. Release one drop into the pouch formed between your eye and eyelid by gently pressing on the &ldquo;finger press&rdquo; area.<br />9. Close your eye and keep it closed. While your eye is still closed, place your index finger against the inside corner of your eye and press against your nose for about two minutes.<br />This will help to stop the medicine from draining through the tear duct to the nose and throat, from where it can be absorbed into other parts of your body. Do not blink or rub your eye.<br />10. Replace the cap. Turn it clockwise until firm resistance is felt (approximately one full turn). Do not overtighten the cap.<br />11. Wash your hands again with soap and water to remove any residue.<br />Wait at least 15 minutes before replacing your contact lenses. These eye drops should be used at least 10 minutes before or after using any other eye preparation.<br />At the end of use, you will notice a small quantity of solution remaining in the bottle. This retained solution cannot be removed and is normal.<br />Discard any remaining solution 4 weeks after opening the bottle.<br />You may find it easier to put drops in your eye while you are sitting or lying down.<br />If you are wearing contact lenses, remove them before putting the drops in your eye.<br />Wait at least 15 minutes before replacing your contact lenses.<br />Be careful not to touch the dropper tip against your eye, eyelid or anything else to avoid contaminating the eye drops.<br />Contaminated eye drops may give you an eye infection.<br />You may feel a slight burning sensation in the eye shortly after using the eye drops.<br />If this persists, or is very uncomfortable, contact your doctor or pharmacist.<br />How long to use it<br />TIMOPTOL helps control your condition but does not cure it. Therefore TIMOPTOL must be used every day. Continue using TIMOPTOL for as long as your doctor prescribes.<br />If you forget to use it<br />If it is almost time for your next dose, skip the dose you missed and use your next dose when you are meant to. Otherwise, use the drops as soon as you remember, and then go<br />back to using them as you would normally.<br />If you are not sure whether to skip the dose, talk to your doctor or pharmacist.<br />Do not use double the amount to make up for the dose that you missed.<br />If you have trouble remembering to use your eye drops, ask your pharmacist for some hints.<br />If you use too much (overdose)<br />If you think that you or anyone else may have swallowed any or all of the contents of a bottle of TIMOPTOL, or used too many drops, immediately telephone your doctor or<br />Poisons Information Centre (telephone 13 11 26) for advice, or go to accident and emergency at your nearest hospital. Do this even if there are no signs of discomfort or poisoning.<br />If TIMOPTOL is accidentally swallowed, or if you use too many drops, you may feel light-headed or dizzy, you may faint, have a very slow pulse rate, or have wheezing or difficulty<br />breathing.<br />While you are using TIMOPTOL<br />Things you must do<br />Have your eye pressure checked when your eye specialist says, to make sure TIMOPTOL is working.<br />If you develop an eye infection, receive an eye injury, or have eye surgery tell your doctor.<br />Your doctor may tell you to use a new container of TIMOPTOL because of possible contamination of the old one, or may advise you to stop your treatment with TIMOPTOL.<br />If you become pregnant while using TIMOPTOL tell your doctor.<br />Tell your doctor before you have an operation that you are using TIMOPTOL, as it may change the effects of some medicines during anaesthesia.<br />If you are about to be started on any new medicine tell your doctor and pharmacist that you are using TIMOPTOL.<br />Things you must not do<br />Do not give TIMOPTOL to anyone else, even if they have the same condition as you.<br />Do not stop using TIMOPTOL without first talking to your doctor.<br />If you stop using your eye drops, your eye pressures may rise again and damage to your eye may occur.<br />Things to be careful of<br />Be careful driving or operating machinery until you know how TIMOPTOL affects you.<br />TIMOPTOL generally does not cause any problems with your ability to drive a car or operate machinery. However, TIMOPTOL may cause blurred vision or dizziness in some people. Make<br />sure you know how you react to TIMOPTOL or that your vision is clear before driving a car or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Tell your doctor or pharmacist as soon as possible if you do not feel well while you are using TIMOPTOL.</strong><br />TIMOPTOL helps most people with high eye pressure and glaucoma, but it may have unwanted side effects in a few people. All medicines can have side effects. Sometimes they are serious,<br />most of the time they are not. You may need medical treatment if you get some of the side effects.<br /><strong>Ask your doctor or pharmacist to answer any questions you may have.<br />Tell your doctor if you notice any of the following and they worry you:<br />problems with your eye/s such as:</strong><br />&bull; blurred vision, double vision or other visual problems<br />&bull; allergic reactions including redness, swelling and/or itching of the eye<br />&bull; burning and stinging of the eyes<br />&bull; irritation or feeling of having something in the eye, dry eyes<br />&bull; discharge<br />&bull; drooping of eyelid/s<br /><strong>difficulty thinking or working because of:</strong><br />&bull; headache<br />&bull; tiredness, weakness<br />&bull; ringing or buzzing in the ears<br />&bull; difficulty sleeping, nightmares<br />&bull; changes in mood such as depression, memory loss<br /><strong>stomach or bowel problems</strong><br />&bull; feeling sick (nausea), upset stomach<br />&bull; diarrhoea<br />&bull; dry mouth<br /><strong>changes in the way your hands and feet feel such as:</strong><br />&bull; cold hands or feet<br />&bull; numbness, tingling and colour change (white, blue then red) in fingers when exposed to the cold (Raynaud&#39;s Phenomenon)<br />&bull; numbness or tingling in the fingers or toes<br /><strong>cough<br />hair loss or thinning<br />less desire for sex<br />sexual dysfunction<br />muscle pain</strong><br />These are usually mild side effects of TIMOPTOL.<br /><strong>Tell your doctor immediately if you notice any of the following:</strong><br />&bull; fast or irregular heart beats, also called palpitations<br />&bull; dizziness and light-headedness, which may be due to low blood pressure<br />&bull; skin rash, itching<br />&bull; swelling of the hands, feet, ankles or legs<br />These may be serious side effects. You may need urgent medical attention.<br />Serious side effects are rare.<br /><strong>If any of the following happen, stop using TIMOPTOL and tell your doctor immediately or go to accident and emergency at your nearest hospital:</strong><br />&bull; wheezing, difficulty in breathing, shortness of breath<br />&bull; very slow pulse, chest pain<br />&bull; fainting<br />&bull; swelling of the face, lips, mouth, tongue or throat which may cause difficulty in breathing or swallowing<br />&bull; severe and sudden onset of pinkish, itchy swellings on the skin, also called hives or nettlerash<br />These are serious side effects. You may need urgent medical attention. These side effects are rare.<br /><strong>Other side effects not listed above may also occur in some patients. Tell your doctor if you notice any other effects.</strong><br />Do not be alarmed by this list of possible side effects. You may not experience any of them.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Keep your eye drops in a cool place. Do not store above 30&deg;C.<br />Do not store it or any other medicine in the bathroom or near a sink.<br />Do not leave it in the car or on window sills.<br />Do not carry the eye drops in pockets of your clothes.</strong><br />Heat and dampness can destroy some medicines.<br /><strong>Keep the eye drops away from direct light.<br />Keep it where children cannot reach it.</strong><br />A locked cupboard at least one-and-a-half metres above the ground is a good place to store medicines.<br />Do not leave the lid off the bottle for any length of time to avoid contaminating the eye drops.</p><p><strong><em>Disposal</em></strong><br /><strong>Write the date on the bottle when you open the eye drops and throw out any remaining solution after four weeks.</strong><br />Eye drops contain a preservative which helps prevent germs growing in the solution for the first four weeks after opening the bottle. After this time there is a greater risk that the drops may<br />become contaminated and cause an eye infection. A new bottle should be opened.<br /><strong>If your doctor tells you to stop using the eye drops or they have passed their expiry date, ask your pharmacist what to do with any remaining solution.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Ingredients</strong><br /><strong>Active ingredient:</strong><br />&bull; TIMOPTOL 0.25% - timolol maleate, equivalent to timolol 0.25%<br /><br /><strong>Inactive ingredients:</strong><br />&bull; dibasic sodium phosphate<br />&bull; monobasic sodium phosphate<br />&bull; sodium hydroxide<br />&bull; benzalkonium chloride as preservative</p><p>&nbsp;</p><p><strong>Warning for Benzalkonium Chloride:</strong><br />- May cause eye irritation<br />- Avoid contact with soft contact lenses.<br />- Remove contact lenses prior to application and wait at least; 15 Minutes before reinsertion contact lens .<br />- Known to discolor soft contact lenses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                TIMOPTOL comes as eye drops in a 5 mL dropper pack. It is available in two strengths.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder:</strong><br />Mundipharma Pty Limited, located at 88 Phillip Street, Sydney NSW 2000 Australia</p><p><strong>Manufacturer and packaging site :</strong><br />Laboratoires Merck Sharp &amp; Dohme Chibret, Mirabel<br />Route de Marsat - Riom 63963 CLERMONT<br />FERRAND CEDEX 9 France.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was prepared in April 2016.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>تُستخدم قطرة تيموبتول لتخفيف ارتفاع الضغط في العينين لعلاج المياه الزرقاء. المياه الزرقاء حالة مرضيّة قد يرتفع فيها ضغط السائل في العينين. ومع ذلك، قد يكون لدى بعض المرضى المصابين بالمياه الزرقاء ضغط طبيعي في العينين.<br />بالإضافة إلى ذلك، قد لا يتعرّ ض بعض المرضى الذين يعانون من ارتفاع ضغط العينين للإصابة بالمياه الزرقاء.<br />تحدث المياه الزرقاء عادةً نتيجة تراكم السائل المتدفق عبر العين. ويحدث هذا التراكم بسبب استنزاف السائل في العينين ببطء شديد أكثر من ضخّه إليهما. ونظرًا لاستمرار دخول السائل الجديد إلى العينين، فضلاً عن السائل الموجود بهما بالفعل،<br />يواصل الضغط ارتفاعه. وقد يُسبب هذا الارتفاع في الضغط تلفًا في الجزء الخلفي من العينين؛ مما يؤدي إلى فقدان تدريجي في الرؤية. وقد يتطور تلف العينين ببطء شديد بحيث لا يعلم المريض بفقدانه التدريجي في الرؤية. وحتى في بعض الأحيان<br />يُصاحب ضغط العينين الطبيعي تلف في الجزء الخلفي من العينين.<br />عادةً لا توجد أعراض لمرض المياه الزرقاء. وتكمن الطريقة الوحيدة للتعرف على الإصابة بالمياه الزرقاء في فحص ضغط العينين والعصب البصري ومجال الإبصار على يد أحد متخصصي طب العيون أو طبيب عيون. وإذا لم تخضع المياه<br />الزرقاء للعلاج، فقد تؤدي إلى مشكلات خطيرة. وقد لا تصاب بأعراض، إلا أن المياه الزرقاء قد تؤدي في النهاية إلى العمى الكلّي. وفي حقيقة الأمر، عدم معالجة المياه الزرقاء أحد أكثر الأسباب شيوعًا للإصابة بالعمى<br />وبالرغم من أن قطرة تيموبتول تساعد في التحكم في الإصابة بالمياه الزرقاء، إلا أنها لا تشفيها.<br />تُستخدم قطرة تيموبتول، إما بمفردها أو بمصاحبة قطرات أخرى أو أدوية للعينين، لخفض ارتفاع الضغط داخل العينين.<br />تخفف قطرة تيموبتول الضغط داخل العينين بتقليل إنتاج السوائل.<br />تنتمي قطرة تيموبتول إلى عائلة من الأدوية تُعرف باسم مثبطات بيتا.<br />لا تُسبب قطرة تيموبتول الإدمان.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>موانع الاستعمال<br />يُرجى تجنّب استعمال قطرة تيموبتول إذا كان المريض مصابًا بحساسية منها أو أي من المكوّنات المذكورة في نهاية هذه النشرة.<br />يُمنع استعمال قطرة تيموبتول في الحالات التالية:</strong><br />&bull; إذا كان المريض مصابًا الآن أو سبق له أن أُصيب في وقت سابق بمشكلات حادة في التنفس مثل الربو، أو له تاريخ مرضي للإصابة بالربو، أو مرض الانسداد الرئوي المزمن (انتفاخ الرئة)، أو غير ذلك من مشكلات التنفس<br />&bull; إذا كان المريض مصابًا ببعض الحالات المرضيّة بالقلب، مثل بطء معدل ضربات القلب، أو عدم انتظام ضربات القلب، أو قصور القلب.<br />يُرجى عدم استعمال قطرة تيموبتول إذا كانت المريضة تُرضع رضاعةً طبيعية أو تعتزم ذلك.<br />فقد يمتص طفل المريضة هذا الدواء من لبن الأم، ومن ثم توجد احتمالية لتعرّض الطفل للأذى.<br />يُرجى عدم وضع قطرات العين بداخل العينين عند ارتداء عدسات لاصقة ليّنة.<br />فقد تترك المادة الحافظة في قطرة تيموبتول (كلوريد البنزالكونيوم) أثرًا على العدسات اللاصقة اللينة. لذا؛ يمكن للمريض وضع العدسات اللاصقة اللينة مرة أخرى في العينين بعد مرور 15 دقيقة على الأقل من الانتهاء من استعمال قطرة تيموبتول.<br />يُمنع استعمال قطرة تيموبتول في الحالات التالية:<br />&bull; كسر السدادة المحيطة بالغطاء<br />&bull; بدا على الزجاجة علامات العبث بها.<br />&bull; انقضاء تاريخ انتهاء الصلاحية على العبوة.<br />فإذا استخدم المريض هذا الدواء بعد انقضاء تاريخ انتهاء الصلاحية، فربما لا يؤدي عمله.<br />في حالة عدم التأكد مما إذا كان ينبغي البدء في استعمال قطرة تيموبتول أم لا، يُرجى التحدث إلى الطبيب.<br />تجنّب استعمال قطرة تيموبتول مع الأطفال.<br />إذ لم تتحدد بعد سلامة قطرة تيموبتول وفاعليته مع الأطفال.</p><p><br /><strong>قبل البدء في استعمال الدواء<br />يُرجى التحدث إلى الطبيب في الحالات التالية:</strong><br />1. إذا كانت المريضة حاملاً أو تعتزم ذلك<br />إذ سيناقش الطبيب مخاطر استعمال قطرة تيموبتول وفوائدها أثناء الحمل، ومن ثم قد يُتخذ القرار بشأن ما إذا كان ينبغي استعمالها أم لا.<br />2. إذا كان المريض مصابًا بأي حالة مرضيّة فيما مضى أو سبق له الإصابة بذلك، لا سيما الحالات المرضيّة التالية:<br />&minus; مشكلات في القلب (مثل مرض القلب التاجي، أو قصور القلب، أو انخفاض ضغط الدم)<br />&minus; اضطرابات في معدل ضربات القلب (مثل بطء ضربات القلب أو عدم انتظامها)<br />&minus; مشكلات في ضعف الدورة الدموية (مثل متلازمة رينو)<br />&minus; مشكلات في الرئة أو التنفس (مثل الربو أو مرض الانسداد الرئوي المزمن)<br />&minus; مرض السكّري أو غيره من مشكلات السكر في الدم<br />&minus; مرض بالغدة الدرقية<br />3. إذا كان المريض يستعمل بالفعل قطرة أخرى من نوع مثبطات بيتا<br />لا يُوصى باستعمال قطرتين من مثبطات بيتا في نفس الوقت.<br />4. إذا كان لدى المريض تاريخ مرضي لمشكلات الحساسية، بما في ذلك الإكزيما، والحمى القراصية أو حمى القش.<br />5. إذا كان المريض يعاني من أي حساسية تجاه أي أدوية أخرى أو أي مواد أخرى، مثل الأطعمة أو المواد الحافظة أو الصبغات.<br />إذا لم يبلّغ المريض طبيبه حول أي مما سبق، فيُرجى إبلاغه قبل استعمال قطرة تيموبتول.</p><p><br /><strong>تناول الأدوية الأخرى<br />يُرجى التحدث إلى الطبيب في حالة تناول أي أدوية أخرى، بما في ذلك الأدوية التي يشتريها المريض من دون وصفة طبية من الصيدلية أو المحلات التجارية الكبرى أو محلات الأطعمة الصحيّة. فقد تتعارض بعض الأدوية وقطرة تيموبتول مع<br />بعضها البعض.</strong><br /><strong>وتتضمن تلك الأدوية ما يلي:</strong><br />&bull; الأدوية المُستخدمة لارتفاع ضغط الدم أو الحالات المرضيّة بالقلب، بما في ذلك مجموعة من الأدوية تُسمى مثبطات بيتا<br />&bull; الديجوكسين، وهو أحد الأدوية المُستخدمة لعلاج قصور القلب<br />&bull; الكينيدين، وهو أحد الأدوية المُستخدمة لعلاج عدم انتظام ضربات القلب<br />&bull; الأدوية التي تُعالج الاكتئاب<br />&bull; الأدوية التي تُعالج مرض السكّري</p><p><br /><strong>قد تتأثر تلك الأدوية بقطرة تيموبتول، أو قد تؤثر في كفاءة عملها. لذا؛ ربما يحتاج المريض إلى كميات مختلفة من أدويته، أو قد يحتاج إلى تناول أدوية مختلفة.<br />ولدى الطبيب أو الصيدلاني مزيد من المعلومات حول الأدوية التي ينبغي الحذر منها أو تجنّبها أثناء استعمال قطرة تيموبتول.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>الكمية المُستخدمة<br />سوف يخبر الطبيب مريضه بعدد القطرات التي يحتاج إلى استعمالها كل يوم.<br />يُرجى عدم استعمال قطرة تيموبتول سوى بوصفة طبية من الطبيب.<br />عند استعمال قطرة تيموبتول بمفردها، فإن الجرعة المعتادة للبالغين قطرة واحدة ثلاث مرات في اليوم، في إحدى العينين أو كلتيهما. يُرجى<br />اتباع جميع التوجيهات التي أعطاها الطبيب بعناية.<br />وقد تختلف هذه التوجيهات عن المعلومات التي تتضمنها هذه النشرة.<br />يُرجى استخدام قطرة تيموبتول يوميًا، في نفس الموعد تقريبًا من كل يوم، ما لم يذكر الطبيب للمريض خلاف ذلك.<br />سيكون لاستخدام قطرة العين في نفس التوقيت التأثير الأمثل على ضغط العين. وسيساعد المريض كذلك على تذكر وقت استعمال القطرة.<br />بعد استخدام قطرة تيموبتول؛ يُرجى الانتظار لمدة 5 دقائق على الأقل قبل وضع أي قطرة أخرى في العينين.<br />طريقة الاستعمال<br />تعليمات حول كيفية استعمال زجاجة قطرة العين<br />الضغط بالإصبع). ويُرجى قراءة التعليمات قبل استخدام الزجاجة. عند إعادة الغطاء إلى موضعه، يُرجى تدويره في اتجاه عقارب الساعة حتى تشعر بمقاومة ثابتة (تقريبًا دورة ) &quot;finger push&quot; تحتوي هذه الزجاجة على منطقة فريدة تخص منطقة<br />واحدة كاملة).<br />وتجنّب المبالغة في إغلاقه.<br />قبل فتح الزجاجة للمرة الأولى<br />تأكّد من عدم إزالة شريط الأمان من واجهة الزجاجة. فإذا كان الشريط مقطوعًا، فيُرجى عدم استخدام الزجاجة، وإعادتها إلى الصيدلاني سيلاحظ المريض مساحة صغيرة بين الغطاء والزجاجة. هذا الأمر طبيعي.<br />كيفية استخدام الزجاجة<br />يُرجى قراءة هذه النشرة بعناية قبل استخدام الزجاجة للمرة الأولى. وإذا كان لدى المريض أي أسئلة، فيُرجى سؤال الطبيب أو الصيدلاني.<br />إذا كان المريض مرتديًا عدسات لاصقة، فيُرجى إزالتها قبل وضع القطرة في العينين.<br />1. يُرجى غسل اليدين جيدًا بالماء والصابون.<br />2. لفتح الزجاجة للمرة الأولى، يُقطع شريط السلامة لكسر السدادة. ثم بعد ذلك، يمسك المريض الزجاجة لأعلى، ويدير الغطاء في اتجاه الأسهم حتى يتمكن من رفعها.</p><p><br />الضغط بالإصبع) على جانب الزجاجة بين الخطّين الرأسيين. ) &quot;finger push&quot; 3. حدد مكان منطقة<br />الضغط بالإصبع)، وضع الإصبع الآخر على الجانب الآخر من الزجاجة (كما هو مبيّن). وتجنّب إدخال أصابعك في قاعدة الزجاجة. ) &quot;finger push&quot; 4. يُرجى إمساك الزجاجة بالمقلوب بيدٍ واحدة، مع وضع إصبع الإبهام أو السبابة على منطقة<br />5. باستخدام يدك الأخرى، يُرجى سحب جفنك السفلي بلطف لتكوين جَيَبة.<br />6. يُرجى إمالة الرأس إلى الخلف والنظر لأعلى.<br />7. أمسِك الزجاجة رأسيًا، ثم ضع طرفها بالقرب من الجفن السفلي كما هو موضّح في الرسم. ويُمنع لمس الزجاجة للعين.<br />الضغط بالإصبع) بلطف. ) &quot;finger push&quot; 8. يُحرر المريض قطرة واحدة داخل الجَيَبة المكونة بين العين والجفن بالضغط على منطقة<br />9. يغلق المريض عينيه، ويستمر في إغلاقها. يضع المريض، أثناء إغلاق عينيه، إصبعه السبابة على الزاوية الداخلية للعين، ثم الضغط على الأنف لمدة دقيقتين تقريبًا. فهذا سيساعد على منع نفاد الدواء عبر القناة المسيلة للدموع إلى الأنف أو الحلق،<br />والتي قد يُمتص منها الدواء في أجزاء أخرى من جسم المريض. ويُمنع الطرف بالعينين أو دعكها.<br />10 . أعِد الغطاء إلى موضعه. ثم أدِره في اتجاه عقارب الساعة حتى تشعر بمقاومة ثابتة (تقريبًا دورة واحدة كاملة). ويُرجى تجنّب المبالغة في إحكام غلق الغطاء.<br />11 . يغسل المريض يديه مرة أخرى بالماء والصابون لإزالة أي بقايا. وينتظر لمدة 15 دقيقة على الأقل قبل وضع العدسات اللاصقة مرة أخرى.<br />ينبغي استعمال قطرات العين لمدة 10 دقائق على الأقل قبل استعمال أي مستحضر آخر للعين أو بعده.<br />۰،۲٥ ٪ وزن/حجم قطرات للعين، محلول<br />۰،٥ ٪ وزن/حجم قطرات للعين، محلول<br />وفي نهاية الاستعمال، سوف تلاحظ كمية صغيرة من المحلول متبقية في الزجاجة. لا يمكن إزالة هذا المحلول المحتجز، وهذا أمرٌ طبيعي.<br />يُرجى التخلّص من أي محلول متبقٍ بعد 4 أسابيع من فتح الزجاجة.<br />قد يجد المريض من الأسهل وضع قطرات في عينيه أثناء الجلوس أو الاستلقاء.<br />إذا كان المريض مرتديًا عدسات لاصقة، فيُرجى إزالتها قبل وضع القطرة في العينين.<br />وينتظر لمدة 15 دقيقة على الأقل قبل وضع العدسات اللاصقة مرة أخرى.<br />ويُحذر لمس طرف القطرة أمام العين أو الجفن أو أي شيء آخر لتجنّب تعرّض قطرة العين للتلوث.<br />فقد تسبب قطرة العين الملوّثة إصابة عين المريض بالعدوى.<br />قد يشعر المريض بإحساس حارق طفيف في العين بعد وقت قصير من استعمال قطرة العين.<br />فإذا استمر هذا الحرقان، أو كان غير مريح بدرجة كبيرة، فيُرجى الاتصال بالطبيب أو الصيدلاني.<br />مدّة الاستعمال<br />تساعد قطرة تيموبتول في التحكم في الإصابة بالمياه الزرقاء، إلا أنها لا تشفيها. لذا؛ يجب استعمال قطرة تيموبتول كل يوم. ويُرجى<br />الاستمرار في استعمال القطرة للمدة التي وصفها الطبيب.<br />عند نسيان استعمال الدواء<br />إذا حان وقت الجرعة التالية تقريبًا، فيُرجى تجاوز الجرعة التي نسيها المريض، وأخذ الجرعة التالية عند حلول وقتها. وبدلاً من ذلك، يمكن استعمال القطرة وقتما يتذكر المريض، ثم العودة مجددًا إلى استعمالها كما هو معتاد.<br />وإذا لم يكن المريض متأكدًا من تجاوز الجرعة أو لا، فيُرجى التحدث إلى الطبيب أو الصيدلاني.<br />يُمنع مضاعفة الكمية لتعويض الجرعة الفائتة.<br />إذا كان لدى المريض مشكلة في تذكر استعمال القطرة، فيُرجى طلب بعض النصائح من الصيدلاني.<br />في حالة الاستعمال المفرط (الجرعة المفرطة)<br />13 ) لطلب النصيحة، أو الذهاب إلى قسم الحوادث 11 إذا ظنّ المريض أو أي شخص أنه ربما ابتلع أيًا من محتويات زجاجة تيموبتول، أو أفرط في استعمال القطرة، فيُرجى على الفور الاتصال بالطبيب أو مركز معلومات السموم (رقم الهاتف 26<br />أو الطوارئ في أقرب مستشفى. ويُرجى إجراء ذلك حتى إذا لم تكن ثمة أي أعراض بالتعب أو التسمم.<br />في حالة ابتلاع المريض من قطرة تيموبتول عن طريق الخطأ، أو في حالة تجاوزه القطرات، قد يشعر بدوار أو دوخة، وقد يتعرّض للإغماء، أو يعاني من بطء شديد في معدل نبضات القلب، أو يعاني من صعوبة في التنفس أو التنفس بصفير.<br />أثناء استعمال قطرة تيموبتول<br />الأمور الواجبة على المريض<br />يُرجع فحص ضغط العين عند طلب اختصاصي أمراض العيون ذلك؛ للتأكد من فاعلية قطرة تيموبتول.<br />إذا تعرّض المريض لعدوى بالعين، أو تلقّى إصابة بها، أو خضع لعملية جراحية بالعين، فيُرجى التحدث إلى الطبيب.<br />قد يطلب الطبيب من المريض استعمال عبوة جديدة من قطرة تيموبتول؛ نظرًا لاحتمال تعرّض العبوة القديمة للتلوث، أو قد ينصحه بوقف العلاج بها.<br />إذا كانت المريضة حاملاً أثناء استعمال قطرة تيموبتول، فيُرجى التحدث إلى الطبيب.<br />يُرجى من المريض إبلاغ الطبيب قبل إجراء عملية جراحية باستعماله قطرة تيموبتول؛ حيث قد تغيّر القطرة من تأثيرات بعض الأدوية أثناء التخدير.<br />إذا كان المريض على وشك البدء في تناول أي دواء جديد، فيُرجى التحدث إلى الطبيب أو الصيدلاني عند استعمال قطرة تيموبتول.<br />موانع الاستعمال<br />يُحظر إعطاء قطرة تيموبتول لأي شخص آخر، حتى إذا كانت لديه نفس الحالة المرضيّة التي يعاني منها المريض.<br />يُمنع التوقّف عن استعمال قطرة تيموبتول من دون التحدث إلى الطبيب أولاً.<br />ففي حالة التوقّف عن استعمال القطرة، قد يتعرض ضغط العين إلى الارتفاع مجددًا، وقد تتعرّض العين للضرر.<br />الأمور الواجب الحذر منها<br />يُرجى توخي الحذر عند القيادة أو تشغيل الماكينات إلى أن يعلم المريض مدى تأثير قطرة تيموبتول.<br />وبوجهٍ عام، لا تسبب قطرة تيموبتول أي مشكلات على قدرة المريض على قيادة السيارة أو تشغيل الماكينات. ومع ذلك، قد يسبب تيموبتول عدم وضوح في الرؤية مع بعض الأشخاص. لذا؛ يُرجى أن يتأكد المريض من مدى تفاعله مع دواء<br />تيموبتول أو من وضوح رؤيته قبل قيادة السيارة أو تشغيل الماكينات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>يُرجى التحدث إلى الطبيب أو الصيدلاني في أقرب وقتٍ ممكن عند شعور المريض بالتعب أثناء استعمال قطرة تيموبتول.<br />تساعد قطرة تيموبتول أغلب المرضى المصابين بارتفاع ضغط العين أو المياه الزرقاء، إلا أنها قد تخلّف آثارًا جانبية مع بعض المرضى. وقد يكون لجميع الأدوية آثار جانبية. أحيانًا ما تكون هذه الآثار خطيرة، إلا أنها غير ذلك في معظم الأحيان.<br />وقد يحتاج المريض إلى علاج طبي إذا تعرّ ض لبعض الآثار الجانبية.<br />لذا؛ يُرجى طلب الإجابة من الطبيب أو الصيدلاني على الأسئلة التي قد تتبادر إلى ذهن المريض.<br />كما يُرجى التحدث إلى الطبيب إذا لاحظ المريض أيًا مما يلي وتسبب ذلك في قلقه:<br />مشكلات في العينين مثل:<br />&bull; عدم وضوح الرؤية أو الرؤية المزدوجة أو غير ذلك من مشكلات الإبصار<br />&bull; تفاعلات حساسية، بما في ذلك إصابة العينين بالاحمرار أو الحكة أو الهياج<br />&bull; حرقان وشعور باللسع في العينين<br />&bull; هياج في العين أو الشعور بوجود شيء ما في العين، جفاف العينين<br />&bull; إفرازات العينين<br />&bull; تدلّي الجفنين<br />صعوبة في التفكير أو العمل بسبب:<br />&bull; صداع<br />&bull; التعب، الضعف<br />&bull; صوت رنين أو طنين في الأذنين<br />&bull; صعوبة في النوم، كوابيس<br />&bull; تغيّرات في الحالة المزاجية، مثل الاكتئاب أو فقدان الذاكرة<br />مشكلات في المعدة أو الأمعاء<br />&bull; الشعور بالإعياء (غثيان)، اضطراب في المعدة<br />&bull; الإسهال<br />&bull; جفاف الفم<br />تغيرات في الطريقة التي تشعر بها اليدان والقدمان، مثل:<br />&bull; برودة اليدين أو القدمين<br />&bull; تنميل في الأظافر وشعور بالوخز وتغيّر لونها (الأبيض، الأزرق، ثم الأحمر) عند تعرّضها للبرودة (ظاهرة رينو)<br />&bull; الشعور بالتنميل أو الوخز في أصابع اليدين أو القدمين<br />السعال<br />تساقط الشعر أو تخففه<br />تراجع الرغبة الجنسية<br />الضعف الجنسي<br />ألم في العضلات<br />وعادةً ما تكون هذه الأعراض آثارًا جانبية خفيفة لقطرة تيموبتول.<br />لذا؛ يُرجى التحدث إلى الطبيب فورًا عند ملاحظة أي من الآثار الجانبية التالية:<br />&bull; سرعة ضربات القلب أو عدم انتظامها، وهو ما يُعرف أيضًا باسم خفقان القلب<br />&bull; الدوخة والدوار، والذي قد يكون بسبب انخفاض ضغط الدم<br />&bull; طفح جلدي، حكة جلدية<br />&bull; تورّم اليدين أو القدمين أو الكاحلين أو الساقين<br />وقد تكون هذه الآثار الجانبية خطيرة. وقد تحتاج إلى رعاية طبية عاجلة.<br />إلا أن الآثار الجانبية الخطيرة نادرة الحدوث.<br />إذا حدثت أي من الأعراض التالية، فيُرجى التوقف عن استعمال قطرة تيموبتول، والتحدث إلى الطبيب على الفور، أو الذهاب إلى أقرب قسم للحوادث أو الطوارئ في أقرب مستشفى:<br />&bull; التنفّس بصفير، صعوبة التنفس، ضيق في التنفس<br />&bull; البطء الشديد في نبضات القلب، ألم في الصدر<br />&bull; الإغماء<br />&bull; تورّم الوجه أو الشفتين أو الفم أو اللسان أو الحلق، والذي قد يُسبب صعوبةً في التنفس أو البلع<br />&bull; بدء ظهور تورمات خطيرة ومفاجئة وردية اللون ومثيرة للحكة على الجلد، والتي تُعرف أيضًا باسم الحُمى القراصية أو حساسية الجلد<br />هذه آثار جانبية خطيرة. وقد تحتاج إلى رعاية طبية عاجلة. إلا أن هذه الآثار الخطيرة نادرة الحدوث.<br />قد تحدث أيضًا آثار جانبية أخرى غير مذكورة أعلاه مع بعض المرضى. لذا؛ يُرجى التحدث إلى الطبيب عند ملاحظة أي آثار أخرى.<br />يُرجى عدم القلق من هذه القائمة للآثار الجانبية المحتملة. فقد لا تتعرض لأيٍ منها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تُحفظ قطرة العين في مكان بارد . لا يخزن في درجة حرارة أعلى من 30 درجة مئوية<br />يُمنع حفظ القطرة أو أي دواء آخر في الحمّام أو بالقرب من المصرِف.<br />يجب عدم ترك القطرة في السيارة أو على عتبات النوافذ.<br />يجب عدم حمل قطرة العين في جيوب الملابس.<br />فقد تؤدي الحرارة والرطوبة إلى تلف بعض الأدوية.<br />تُحفظ قطرة العين بعيدًا عن الضوء المباشر.<br />تُحفظ بعيدًا عن متناول الأطفال.<br />ومن الأماكن الجيدة لتخزين الأدوية خزانة مقفلة تبعد عن الأرض مترًا ونصف المتر على الأقل.<br />يجب عدم ترك الغطاء خارج الزجاجة لأي مدة لتجنّب تعرّض القطرة للتلوث.<br />التخلص من القطرة<br />يُرجى كتابة تاريخ فتح قطرة العين على الزجاجة، والتخلص من أي محلولٍ متبقٍ بعد أربعة أسابيع.<br />تحتوي قطرة العين على مادة حافظة تساعد على الوقاية من الجراثيم التي تنمو في المحلول خلال<br />الأسابيع الأربعة الأولى بعد فتح الزجاجة. وبعد هذه الفترة، توجد خطورة أكبر من تعرّض القطرة للتلوث، والتسبب في عدوى العين. لذا؛ ينبغي فتح زجاجة جديدة.<br />إذا طلب الطبيب من مريضه إيقاف استعمال قطرة العين، أو أنها قد تجاوزت تاريخ انتهاء صلاحيتها، فيُرجى سؤال الصيدلاني عمّا يجب فعله مع أي محلولٍ متبقٍ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المكوّنات<br />المادة الفعّالة:<br />&bull; تيموبتول % 0.25 - تيمولول ماليات، بما يعادل % 0.25 من تيمولول<br /><br />تحذير البنزالكونيوم كلوريد:<br />- من المحتمل ان تسبب تهيج بسيط للعين.<br />- يجب عدم وضع القطرة مع العسات الاصقة<br />- يجب خلع العدسة قبل وضع القطرة . وعدم ارتدائة لمد 15 دقيقة بعد وضع القطرة</p><p>- يجب التعرف ان هذه القطره قد تسبب تغير لون العدسات الاصقة.</p><p><br />المواد غير الفعالة:<br />&bull; فوسفات الصوديوم ثنائي القاعدة<br />&bull; فوسفات الصوديوم أحادي القاعدة<br />&bull; هيدروكسيد الصوديوم<br />&bull; كلوريد البنزالكونيوم كمادة حافظة</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>يأتي دواء تيموبتول في صورة قطرات للعين في عبوة قطّارة 5مل. وهذه القطّارة متوفرة في محلولين غير مخففين.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الشركة المالكة لحقوق التسويق:<br />منديفارما ليمتد الواقعة في شارع<br />88 فيليب, سيدني ن س 2000 أستراليا<br />الشركة الصانعة و التغليف بواسطة<br />معامل شركة ميرك شارب ودوم شيبريت<br />ميرابيل بلانت، طريق مارسات ، ريوم ٦۳۹٦۳<br />كليرمون فيران سيدكس ۹، فرنسا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أُعدَّت هذه النشرة في أبريل 2016
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Timoptol® 0.25% w/v Eye Drops Solution
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ‘Timoptol’ 0.25% w/v Eye Drops Solution contains timolol maleate equivalent to
0.25% w/v solution of timolol with preservative.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eye drops solution.
Clear, colourless to light yellow, sterile eye drops solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Timoptol&rsquo; Eye Drops Solution is a beta-adrenoreceptor blocking agent used topically<br />in the reduction of elevated intra-ocular pressure in various conditions including<br />following: patients with ocular hypertension; patients with chronic open-angle<br />glaucoma including aphakic patients; some patients with secondary glaucoma.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Recommended therapy is one drop 0.25% solution in the affected eye twice a day.<br />When using nasolacrimal occlusion or closing the eyelids for 2 minutes, the systemic<br />absorption is reduced. This may result in a decrease in systemic side effects and an<br />increase in local activity.<br />If clinical response is not adequate, dosage may be changed to one drop 0.5% solution<br />in each affected eye twice a day. If needed, &lsquo;Timoptol&rsquo; may be used with other<br />agent(s) for lowering intra-ocular pressure. The use of two topical beta-adrenergic<br />blocking agents is not recommended (see 4.4 &lsquo;Special warnings and precautions for<br />use&rsquo;).<br />Intra-ocular pressure should be reassessed approximately four weeks after starting<br />treatment because response to &lsquo;Timoptol&rsquo; may take a few weeks to stabilise.<br /><br />Provided that the intra-ocular pressure is maintained at satisfactory levels, many<br />patients can then be placed on once-a-day therapy.<br />&nbsp;</p><p><u><strong>Transfer from other agents</strong></u><br />When another topical beta-blocking agent is being used, discontinue its use after a full<br />day of therapy and start treatment with &lsquo;Timoptol&rsquo; the next day with one drop of<br />0.25% &lsquo;Timoptol&rsquo; in each affected eye twice a day. The dosage may be increased to<br />one drop of 0.5% solution in each affected eye twice a day, if the response is not<br />adequate.<br />When transferring a patient from a single anti-glaucoma agent other than a topical<br />beta-blocking agent, continue the agent and add one drop of 0.25% &lsquo;Timoptol&rsquo; in each<br />affected eye twice a day. On the following day, discontinue the previous agent<br />completely, and continue with &lsquo;Timoptol&rsquo;. If a higher dosage of &lsquo;Timoptol&rsquo; is<br />required, substitute one drop of 0.5% solution in each affected eye twice a day.<br />&lsquo;Timoptol&rsquo; Eye Drops Solution is also available as &lsquo;Timoptol&rsquo; Unit dose: The Unitdose<br />Dispenser of &lsquo;Timoptol&rsquo; is free from preservative and should be used for patients<br />who may be sensitive to the preservative benzalkonium chloride, or when use of a<br />preservative-free topical medication is advisable.<br />Use in the elderly: there has been wide experience with the use of timolol maleate in<br />elderly patients. The dosage recommendations given above reflect the clinical data<br />derived from this experience.</p><p><u><strong>Paediatric Population</strong></u>:<br />Due to limited data, Timolol could only be recommended for use in primary congenital<br />and primary juvenile glaucoma for a transitional period while a decision is made on a<br />surgical approach and in case of failed surgery while awaiting further options.</p><p><strong>Posology:</strong><br />Clinicians should strongly evaluate the risks and benefits when considering medical<br />therapy with Timolol in paediatric patients. A detailed paediatric history and<br />examination to determine the presence of systemic abnormalities should precede the<br />use of Timolol.<br />No specific dosage recommendation can be given as there is only limited clinical data<br />(see also section 5.1).<br />However, if benefit outweighs the risk, it is recommended to use the lowest active<br />agent concentration available once daily. If IOP could not be sufficiently controlled, a<br />careful up titration to a maximum of two drops daily per affected eye has to be<br />considered. If applied twice daily, an interval of 12 hours should be preferred.<br />Furthermore the patients, especially neonates, should be closely observed after the first<br />dose for one to two hours in the office and closely monitored for ocular and systemic<br />side effects.<br /><br />With regard to paediatric use, the 0.1% active agent concentration might already be<br />sufficient.</p><p><u><strong>Method of administration:</strong></u><br />To limit potential adverse effects only one drop should be instilled per dosing time.<br />Systemic absorption of topically administered &beta;-blockers can be reduced by<br />nasolacrimal occlusion and by keeping the eyes closed as long as possible (e.g. for 3 -<br />5 minutes) after instillation of drops. See also section 4.4, 5.2.</p><p><u><strong>Duration of treatment:</strong></u><br />For a transient treatment in the paediatric population (see also section 4.2 &ldquo;Paediatric<br />Population&rdquo;).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Reactive airway disease including bronchial asthma or a history of bronchial asthma,
severe chronic obstructive pulmonary disease; sinus bradycardia, sick sinus syndrome
sino-atrial block, second- and third-degree atrioventricular block not controlled with
pace-maker, overt cardiac failure, cardiogenic shock.

Hypersensitivity to the active substance or to any of the excipients.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Like other topically applied ophthalmic agents, timolol is absorbed systemically. Due<br />to beta-adrenergic component, timolol, the same types of cardiovascular, pulmonary<br />and other adverse reactions seen with systemic beta-adrenergic blocking agents may<br />occur. Incidence of systemic ADRs after topical ophthalmic administration is lower<br />than for systemic administration. To reduce the systemic absorption, see 4.2.</p><p><u><strong>Cardiac disorders:</strong></u><br />In patients with cardiovascular diseases (e.g. coronary heart disease, Prinzmetal&#39;s<br />angina and cardiac failure) and hypotension therapy with beta-blockers should be<br />critically assessed and the therapy with other active substances should be considered.<br />Patients with cardiovascular diseases should be watched for signs of deterioration of<br />these diseases and of adverse reactions.<br />Due to its negative effect on conduction time, beta-blockers should only be given with<br />caution to patients with first degree heart block.<br />Cardiac failure should be adequately controlled before beginning therapy with<br />&lsquo;Timoptol&rsquo;. Patients with a history of severe cardiac disease should be watched for<br />signs of cardiac failure and have their pulse rates monitored.<br />&nbsp;</p><p><u><strong>Vascular disorders</strong></u><br />Patients with severe peripheral circulatory disturbance/disorders (i.e. severe forms of<br />Raynaud&rsquo;s disease or Raynaud&rsquo;s syndrome) should be treated with caution.</p><p><u><strong>Respiratory disorders:</strong></u><br />Respiratory reactions, including death due to bronchospasm in patients with asthma<br />have been reported following administration of some ophthalmic beta-blockers.<br />&lsquo;Timoptol&rsquo; should be used with caution, in patients with mild/moderate chronic<br />obstructive pulmonary disease (COPD) and only if the potential benefit outweighs the<br />potential risk.</p><p><u><strong>Hypoglycaemia/diabetes</strong></u><br />Beta-blockers should be administered with caution in patients subject to spontaneous<br />hypoglycaemia or to patients with labile diabetes, as beta-blockers may mask the signs<br />and symptoms of acute hypoglycaemia.<br />Beta-blockers may also mask the signs of hyperthyroidism.</p><p><u><strong>Corneal diseases</strong></u><br />Ophthalmic beta-blockers may induce dryness of eyes. Patients with corneal diseases<br />should be treated with caution.</p><p><u><strong>Other beta-blocking agents</strong></u><br />The effect on intra-ocular pressure or the known effects of systemic beta-blockade may<br />be potentiated when timolol is given to the patients already receiving a systemic<br />beta-blocking agent. The response of these patients should be closely observed. The<br />use of two topical beta-adrenergic blocking agents is not recommended (see section<br />4.5).<br />There have been reports of skin rashes and/or dry eyes associated with the use of<br />beta-adrenoreceptor blocking drugs. The reported incidence is small and in most cases<br />the symptoms have cleared when treatment was withdrawn. Discontinuation of the<br />drug should be considered if any such reaction is not otherwise explicable. Cessation<br />of therapy involving beta-blockade should be gradual.</p><p><strong><u>Choroidal detachment</u></strong><br />Choroidal detachment has been reported with administration of aqueous suppressant<br />therapy (e.g. timolol, acetazolamide) after filtration procedures.</p><p><u><strong>Surgical anaesthesia</strong></u><br />Beta-blocking ophthalmological preparations may block systemic beta-agonist effects<br />e.g. of epinephrine (adrenaline). The anaesthesiologist should be informed when the<br />patient is receiving timolol.<br />&lsquo;Timoptol&rsquo; has been generally well tolerated in glaucoma patients wearing<br />conventional hard contact lenses. &lsquo;Timoptol&rsquo; has not been studied in patients wearing<br />lenses made with material other than polymethylmethacrylate (PMMA), which is used<br />to make hard contact lenses.<br />5<br />The Ocumeter&reg; Dispenser of &lsquo;Timoptol&rsquo; contains benzalkonium chloride as a<br />preservative which may be deposited in soft contact lenses; therefore &lsquo;Timoptol&rsquo;<br />should not be used while wearing these lenses. The lenses should be removed before<br />application of the drops and not reinserted earlier than 15 minutes after use.<br />In patients with angle-closure glaucoma, the immediate objective of treatment is to<br />reopen the angle. This requires constricting the pupil with a miotic. &lsquo;Timoptol&rsquo; has<br />little or no effect on the pupil. When &lsquo;Timoptol&rsquo; is used to reduce elevated intraocular<br />pressure in angle-closure glaucoma it should be used with a miotic and not<br />alone.<br />Patients should be advised that if they develop an intercurrent ocular condition (e.g.<br />trauma, ocular surgery or infection), they should immediately seek their physician&rsquo;s<br />advice concerning the continued use of the present multidose container (see 6.6<br />&lsquo;Special precautions for disposal and other handling&rsquo;).<br />There have been reports of bacterial keratitis associated with the use of multiple dose<br />containers of topical ophthalmic products. These containers had been inadvertently<br />contaminated by patients who, in most cases, had a concurrent corneal disease or a<br />disruption of the ocular epithelial surface.</p><p><u><strong>Anaphylactic reactions</strong></u><br />While taking beta-blockers, patients with a history of atopy or a history of severe<br />anaphylactic reaction to a variety of allergens may be more reactive to repeated<br />challenge with such allergens and, may be unresponsive to the usual dose of<br />epinephrine (adrenaline) used to treat anaphylactic reactions.</p><p><u><strong>Paediatric Population:</strong></u><br />Timolol solutions should generally be used cautiously in young glaucoma patients (see<br />also section 5.2).<br />It is important to notify the parents of potential side effects so they can immediately<br />discontinue the drug therapy (see section 4.8). Signs to look for are, for example,<br />coughing and wheezing.<br />Because of the possibility of apnoea and Cheyne-Stokes breathing, the drug should be<br />used with extreme caution in neonates, infants and younger children. A portable<br />apnoea monitor may also be helpful for neonates on Timolol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific drug interaction studies have been performed with timolol maleate.</p><p>There is a potential for additive effects resulting in hypotension and/or marked<br />bradycardia when ophthalmic beta-blockers solution is administered concomitantly<br />with oral calcium-channel blockers, beta-adrenergic blocking agents, antiarrhythmics<br />(including amiodarone), digitalis glycosides, rauwolfia alkaloids,<br />parasympathomimetics, guanethidine.<br /><br />Although &lsquo;Timoptol&rsquo; alone has little or no effect on pupil size, mydriasis resulting<br />from concomitant use of ophthalmic beta-blockers and epinephrine (adrenaline ) has<br />been reported occasionally.</p><p>Potentiated systemic beta-blockade (e.g. decreased heart rate, depression) has been<br />reported during combined treatment with CYP2D6 inhibitors (e.g. quinidine,<br />fluoxetine, paroxetine) and timolol.</p><p>Oral beta-adrenergic blocking agents may exacerbate the rebound hypertension which<br />can follow the withdrawal of clonidine.<br />Close observation of the patient is recommended when a beta-blocker is administered<br />to patients receiving catecholamine-depleting drugs such as reserpine, because of<br />possible additive effects and the production of hypotension and/or marked bradycardia,<br />which may produce vertigo, syncope, or postural hypotension.<br />Oral calcium-channel antagonists may be used in combination with beta-adrenergic<br />blocking agents when heart function is normal, but should be avoided in patients with<br />impaired cardiac function.<br />The potential exists for hypotension, AV conduction disturbances and left ventricular<br />failure to occur in patients receiving a beta-blocking agent when an oral calciumchannel<br />blocker is added to the treatment regimen. The nature of any cardiovascular<br />adverse effects tends to depend on the type of calcium-channel blocker used.<br />Dihydropyridine derivatives, such as nifedipine, may lead to hypotension, whereas<br />verapamil or diltiazem have a greater propensity to lead to AV conduction<br />disturbances or left ventricular failure when used with a beta-blocker.<br />Intravenous calcium channel blockers should be used with caution in patients receiving<br />beta-adrenergic blocking agents.<br />The concomitant use of beta-adrenergic blocking agents and digitalis with either<br />diltiazem or verapamil may have additive effects in prolonging AV conduction time.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Pregnancy</strong></u><br />There are no adequate data for the use of timolol maleate in pregnant women.<br />&lsquo;Timoptol&rsquo; should not be used during pregnancy unless clearly necessary. To reduce<br />the systemic absorption, see 4.2.<br />Epidemiological studies have not revealed malformative effects but show a risk for<br />intra uterine growth retardation when beta-blockers are administered by the oral route.<br />In addition, signs and symptoms of beta-blockade (e.g. bradycardia, hypotension,<br />respiratory distress and hypoglycaemia) have been observed in the neonate when betablockers<br />have been administered until delivery. If &lsquo;Timoptol&rsquo; is administered until<br />delivery, the neonate should be carefully monitored during the first days of life.</p><p><u><strong>Lactation</strong></u><br />Timolol is detectable in human milk. A decision for breastfeeding mothers, either to<br />stop taking &lsquo;Timoptol&rsquo; or stop nursing, should be based on the importance of the drug<br />to the mother.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Possible side effects such as dizziness, visual disturbances, refractive changes,<br />diplopia, ptosis, frequent episodes of mild and transient blurred vision and fatigue may<br />affect some patients&rsquo; ability to drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Like other topically applied ophthalmic drugs, timolol is absorbed into the systemic<br />circulation. This may cause similar undesirable effects as seen with systemic betablocking<br />agents. Incidence of systemic ADRs after topical ophthalmic administration<br />is lower than for systemic administration. The following adverse reactions have been<br />reported with ocular administration of this or other timolol maleate formulations,<br />either in clinical trials or since the drug has been marketed. Additional side effects<br />have been reported in clinical experiences with systemic timolol maleate, and may be<br />considered potential effects of ophthalmic timolol maleate. Also listed are adverse<br />reactions seen within the class of ophthalmic beta-blockers and may potentially occur<br />with &lsquo;Timoptol&rsquo;.</p><p><u><strong>Eye disorders</strong></u><br />ocular: signs and symptoms of ocular irritation, (e.g. burning, stinging, itching,<br />tearing, redness), conjunctivitis, blepharitis, keratitis, dry eyes, decreased corneal<br />sensitivity, blurred vision, corneal erosion. Visual disturbances, including refractive<br />changes (due to withdrawal of miotic therapy in some cases), diplopia, ptosis and<br />choroidal detachment following filtration surgery (see 4.4 &lsquo;Special warnings and<br />precautions for use&rsquo;).</p><p><u><strong>Ear and labyrinth disorders:</strong></u><br />ocular: tinnitus</p><p><u><strong>Cardiac disorders</strong></u><br />ocular: bradycardia, chest pain, arrhythmia, heart block, congestive heart failure,<br />palpitations, cardiac arrest, cardiac failure, oedema;<br />systemic: atrioventricular block (second- or third-degree), sino-atrial block, pulmonary<br />oedema, worsening of arterial insufficiency, worsening of angina pectoris,<br />vasodilation.</p><p><u><strong>Vascular disorders:</strong></u><br />ocular: claudication, hypotension, Raynaud&#39;s phenomenon, cold hands and feet.</p><p><u><strong>Respiratory, thoracic and mediastinal disorders:</strong></u><br />ocular: bronchospasm (predominantly in patients with pre-existing bronchospastic<br />disease), respiratory failure, dyspnoea, cough;<br />systemic: rales.<br /><br /><u><strong>General disorders and administration site conditions:</strong></u><br />ocular: asthenia, fatigue;<br />systemic: extremity pain, decreased exercise tolerance.</p><p><u><strong>Skin and subcutaneous tissue disorders:</strong></u><br />ocular: alopecia, psoriasiform rash or exacerbation of psoriasis, skin rash;<br />systemic: sweating, exfoliative dermatitis.</p><p><u><strong>Immune system disorders:</strong></u><br />ocular: systemic lupus erythematosus, pruritus;<br />systemic: signs and symptoms of allergic reactions including anaphylaxis, angioedema,<br />urticaria, localised and generalised rash, anaphylactic reaction.</p><p><u><strong>Psychiatric disorders:</strong></u><br />ocular: depression, insomnia, nightmares, memory loss;<br />systemic: diminished concentration, increased dreaming.</p><p><u><strong>Nervous system disorders</strong></u><br />ocular: syncope, cerebrovascular accident, cerebral ischemia, headache, dizziness,<br />increase in signs and symptoms of myasthenia gravis, paraesthesia;<br />systemic: vertigo, local weakness</p><p><u><strong>Gastrointestinal disorders:</strong></u><br />ocular: nausea, diarrhoea, dyspepsia, dry mouth dysgeusia, abdominal pain vomiting.</p><p><u><strong>Reproductive system and breast disorders:</strong></u><br />ocular: decreased libido, Peyronie&rsquo;s disease, sexual dysfunction such as impotence;<br />systemic: micturition difficulties.</p><p><u><strong>Metabolism and nutrition disorders:</strong></u><br />ocular: hypoglycaemia;<br />systemic: hyperglycaemia.</p><p><u><strong>Musculoskeletal and connective tissue disorders:</strong></u><br />ocular: myalgia;systemic: arthralgia.</p><p><br /><u><strong>Blood and lymphatic system disorders:</strong></u><br />systemic: non-thrombocytopenic purpura.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There have been reports of inadvertent overdosage with &lsquo;Timoptol&rsquo; resulting in<br />systemic effects similar to those seen with systemic beta-adrenergic blocking agents<br />such as dizziness, headache, shortness of breath, bradycardia, hypotension,<br />bronchospasm, acute cardiac insufficiency and cardiac arrest (see &lsquo;Side effects&rsquo;).</p><p><strong>If overdosage occurs, the following measures should be considered:</strong><br />1. Gastric lavage, if ingested. Studies have shown that timolol does not dialyse<br />readily.<br />2. Symptomatic bradycardia: atropine sulphate, 0.25 to 2 mg intravenously, should<br />be used to induce vagal blockade. If bradycardia persists, intravenous isoprenaline<br />hydrochloride should be administered cautiously. In refractory cases, the use of a<br />cardiac pacemaker may be considered.<br />3. Hypotension: a sympathomimetic pressor agent such as dopamine, dobutamine or<br />noradrenaline should be used. In refractory cases, the use of glucagon has been<br />reported to be useful.<br />4. Bronchospasm: isoprenaline hydrochloride should be used. Additional therapy<br />with aminophylline may be considered.<br />5. Acute cardiac failure: conventional therapy with digitalis, diuretics, and oxygen<br />should be instituted immediately. In refractory cases, the use of intravenous<br />aminophylline is suggested. This may be followed, if necessary, by glucagon,<br />which has been reported useful.<br />6. Heart block (second- or third-degree): isoprenaline hydrochloride or a pacemaker<br />should be used.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antiglaucoma preparations and miotics, Beta-blocking<br />agents, Timolol, ATC code: S01ED01.</p><p><br />Timolol maleate is a non-selective beta-adrenergic receptor blocking agent that does<br />not have significant intrinsic sympathomimetic, direct myocardial depressant, or local<br />anaesthetic activity. Timolol maleate combines reversibly with the beta-adrenergic<br />receptor, and this inhibits the usual biologic response that would occur with<br />stimulation of that receptor. This specific competitive antagonism blocks stimulation<br />of the beta-adrenergic stimulating (agonist) activity, whether these originate from an<br />endogenous or exogenous source. Reversal of this blockade can be accomplished by<br />increasing the concentration of the agonist which will restore the usual biological<br />response.</p><p><br />Unlike miotics, &lsquo;Timoptol&rsquo; reduces IOP with little or no effect on accommodation or<br />pupil size. In patients with cataracts, the inability to see around lenticular opacities<br />when the pupil is constricted is avoided. When changing patients from miotics to<br />&lsquo;Timoptol&rsquo; a refraction might be necessary when the effects of the miotic have passed.</p><p>Diminished response after prolonged therapy with &lsquo;Timoptol&rsquo; has been reported in<br />some patients.</p><p><u><strong>Paediatric Population:</strong></u><br />There is only very limited data available on the use of Timolol (0.25%, 0.5% twice<br />daily one drop) in the paediatric population. In one small, double masked,<br />randomized, published clinical study conducted for a treatment period up to 12 weeks<br />on 105 children (n=71 on Timolol) aged 12 days &ndash; 5 years the data have shown to<br />some extent evidence, that Timolol in the indication primary congenital and primary<br />juvenile glaucoma is effective in short term treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The onset of reduction in intra-ocular pressure can be detected within one-half hour<br />after a single dose. The maximum effect occurs in one or two hours; significant<br />lowering of IOP can be maintained for as long as 24 hours with a single dose.</p><p><u><strong>Paediatric Population:</strong></u><br />As already confirmed by adult data, 80% of each eye drop passes through the<br />nasolacrimal system where it may be rapidly absorbed into the systemic circulation via<br />the nasal mucosa, conjunctiva, nasolacrimal duct, oropharynx and gut, or the skin from<br />tear overflow.<br />Due to the fact that the blood volume in children is smaller than that in adults a higher<br />circulation concentration has to be taken into account. In addition, neonates have<br />immature metabolic enzyme pathways and it may result in an increase in elimination<br />half-life and potentiating adverse events.<br />Limited data show that plasma timolol levels in children after 0.25% greatly exceed<br />those in adults after 0.5%, especially in infants and are presumed to increase the risk of<br />side effects such as bronchospasm and bradycardia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No adverse ocular effects were observed in rabbits and dogs administered &lsquo;Timoptol&rsquo;<br />topically in studies lasting one and two years, respectively. The oral LD50 of the drug is 1,190 and 900 mg/kg in female mice and female rats, respectively.</p><p><br /><u><strong>Carcinogenesis, mutagenesis, impairment of fertility</strong></u><br />In a two-year oral study of timolol maleate in rats there was a statistically significant<br />(p0.05) increase in the incidence of adrenal phaeochromocytomas in male rats<br />administered 300 mg/kg/day (300 times the maximum recommended human oral<br />dose). Similar differences were not observed in rats administered oral doses<br />equivalent to 25 or 100 times the maximum recommended human oral dose.</p><p>In a lifetime oral study in mice, there were statistically significant (p0.05) increases in<br />the incidence of benign and malignant pulmonary tumours, benign uterine polyps and<br />mammary adenocarcinoma in female mice at 500 mg/kg/day (500 times the maximum<br />recommended human dose), but not at 5 or 50 mg/kg/day. In a subsequent study in<br />female mice, in which post-mortem examinations were limited to uterus and lungs, a<br />statistically significant increase in the incidence of pulmonary tumours was again<br />observed at 500 mg/kg/day.</p><p>The increased occurrence of mammary adenocarcinoma was associated with elevations<br />in serum prolactin which occurred in female mice administered timolol at 500<br />mg/kg/day, but not at doses of 5 or 50 mg/kg/day. An increased incidence of<br />mammary adenocarcinomas in rodents has been associated with administration of<br />several other therapeutic agents which elevate serum prolactin, but no correlation<br />between serum prolactin levels and mammary tumours has been established in man.<br />Furthermore, in adult human female subjects who received oral dosages of up to 60 mg<br />of timolol maleate, the maximum recommended human oral dosage, there were no<br />clinically meaningful changes in serum prolactin.</p><p>Timolol maleate was devoid of mutagenic potential when evaluated in vivo (mouse) in<br />the micronucleus test and cytogenetic assay (doses up to 800 mg/kg) and in vitro in a<br />neoplastic cell transformation assay (up to 100 mcg/ml). In Ames tests the highest<br />concentrations of timolol employed, 5,000 or 10,000 mcg/plate, were associated with<br />statistically significant (p0.05) elevations of revertants observed with tester strain<br />TA100 (in seven replicate assays) but not in the remaining three strains. In the assays<br />with tester strain TA100, no consistent dose-response relationship was observed, nor<br />did the ratio of test to control revertants reach 2. A ratio of 2 is usually considered the<br />criterion for a positive Ames test.</p><p>Reproduction and fertility studies in rats showed no adverse effect on male or female<br />fertility at doses up to 150 times the maximum recommended human oral dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium phosphate monobasic 2H2O<br />Sodium phosphate Dibasic, 12H2O<br />Benzalkonium chloride 50% solution<br />Sodium hydroxide<br />Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
Discard ‘Timoptol’ Eye Drops Solution 28 days after opening the bottle.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 25&deg;C. Store the bottle in the outer carton in order to protect from<br />light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The OCUMETER Plus ophthalmic dispenser consists of a translucent high-density<br />polyethylene container with a sealed dropper tip, a flexible fluted side area, which is<br />depressed to dispense the drops, and a two-piece cap assembly. The two-piece cap<br />mechanism punctures the sealed dropper tip upon initial use, then locks together to<br />provide a single cap during the usage period. Tamper evidence is provided by two<br />perforated tabs on the container label extending on to the cap. The OCUMETER Plus<br />ophthalmic dispenser contains 5 ml of solution.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be instructed to avoid allowing the tip of the dispensing container to<br />contact the eye or surrounding structures.</p><p>Patients should also be instructed that ocular solutions, if handled improperly, can<br />become contaminated by common bacteria known to cause ocular infections. Serious<br />damage to the eye and subsequent loss of vision may result from using contaminated<br />solutions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Mundipharma Pty Limited, located at 88 Phillip Street, Sydney NSW 2000 Australia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>